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1.1 Introduction and Specific Aims 
 Hypertension, cognitive impairment, and dementia are significant public health 
problems in the United States (US) and worldwide.  Hypertension, one of the most 
common health problems in adults, affects approximately 65 million individuals in the 
US in 1999-2000 with a prevalence of 31.3% (1).   The prevalence of systolic 
hypertension is directly proportional to age (2).  Among people age 65 years and over in 
the US, more than half had isolated systolic or combined systolic-diastolic hypertension 
(2).  It is estimated that 48% of hypertensive patients aged 25 or older in the US are either 
unaware of or untreated for their condition (3).  
 There will be a dramatic increase in persons with dementia worldwide in the next 
30 years:  it is estimated that 24.3 million people worldwide had dementia in 2001 and 
the number of people affected is expected to double every 20 years to 81.1 million by 
2040 (4).    The prevalence of dementia increases rapidly with advanced age:  it is 
estimated to be below 1% in individuals aged 60–64 years, and doubles every 5 years to 
exceed 30% in people aged 85 years or older in North American and the US (4). 
There is evidence to support a biological relationship between hypertension and 
cognitive impairment and dementia (5-15). In addition to elevated systolic and diastolic 
blood pressure, declining or low diastolic blood pressure may also be a risk factor for 
cognitive impairment and dementia in older age groups (14, 16-21).  However, 
epidemiological studies investigating the relationship between hypertension and lower 
diastolic blood pressure, and cognitive decline in the elderly have provided inconsistent 
results (16, 19, 22-32).    
The effects of hypertension on cognitive impairment may be modified by age 
(33).  As the difference between systolic and diastolic blood pressure changes with age, it 
has been suggested that pulse pressure (defined as systolic blood pressure minus diastolic 
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blood pressure) may provide important information about the effects of blood pressure on 
cognitive outcomes in the elderly(34-35).  Few population-based studies, however, have 
examined the relationship between pulse pressure in late life and cognitive decline (34). 
Randomized clinical trials have shown that antihypertensive treatment produces 
significant reductions in stroke and cardiovascular risk (36), which have been linked to 
greater risk of developing dementia (14, 37-44).  Longitudinal observational studies and 
clinical trials examining the association between antihypertensive therapy and dementia, 
however, do not consistently support the protective effect of antihypertensive treatment 
on the development of dementia (45-51).      
The Sacramento Area Latino Study on Aging (SALSA), a 6-year follow-up study, 
provided a unique opportunity to assess the impact of blood pressure, pulse pressure, and 
antihypertensive treatment over time on decline in cognitive function and dementia risk 
in an older population of Mexican Americans.   The Hispanic population is the fastest 
growing and largest minority population in the US, accounting for one-half of the 
nations’ growth during 2000-2006 (52). The Hispanic population is youthful with 
approximately 7% of individuals aged 60 and older (52). Mexican Americans, the largest 
subgroup of Hispanic Americans, make up approximately two-thirds of US Hispanics 
(52).  About 3 million Mexican American adults had hypertension in 1999 to 2000, with 
prevalence of 29% similar to non-Hispanic white adults (1).  The prevalence of dementia 
in this population was about 5% among those aged 60 and older and 31% among those 
aged 85 and older, similar to that in non-Hispanic Whites.  It is likely that aging in this 
population will lead to an increase of the prevalence of both conditions in coming years. 
In addition, studies have shown that Mexican Americans had increased risk of stroke and 
better post-stroke survival as compared with non-Hispanic Whites (53-54).   Higher 
prevalence of stroke, diabetes and central obesity, lower socio-economic status, poorer 
access to health cares among Mexican Americans as compared with non-Hispanic Whites 
present a great challenge to manage these risk factors associated with cognitive 
impairment (54-56).   
 This study is the first to focus on the relationship between blood pressure, pulse 
pressure and antihypertensive treatment to cognitive decline and dementia incidence in 
the elderly Mexican American population.  The data from this study provide a unique 
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opportunity to better understand the relationship between hypertension and cognition in 
elderly Mexican-Americans.  They may help to identify potentially modifiable risk 
factors for cognitive decline and dementia and to evaluate the usefulness of the treatment 
options to these risk factors.  
 The overall objective of this study is to assess the association between systolic 
and diastolic blood pressure and pulse pressure with cognitive decline in an elderly 
Mexican-American population, and to examine the effect of antihypertensive treatment 
on the incidence of dementia or CIND (clinically impaired but not demented) among 
elderly Mexican-American hypertensive patients, using a population-based cohort study 
design.  Specific aims and hypotheses are:   
Aim 1:  To assess the association of baseline and time-dependent systolic and 
diastolic blood pressure with decline in cognitive function over 6 years of follow-up 
among older Mexican Americans. 
 Hypothesis 1:  Higher baseline and time-dependent systolic blood pressure are 
associated with greater increase in errors in the Modified Mini-Mental State Examination 
(3MSE) and greater decline in the Spanish English Verbal Learning Test (SEVLT) scores 
over time.   
 Hypothesis 2:  Higher baseline and time-dependent diastolic blood pressure are 
associated with greater decline in errors in 3MSE and greater increase in SEVLT scores 
over time. 
 Aim 2:  To test the association of baseline and time-dependent pulse pressure 
with decline in cognitive function over 6 years of follow-up among older Mexican 
Americans. 
 Hypothesis:  Higher baseline and time-dependent pulse pressure are associated with 
greater increase in errors in 3MSE and greater decline in SEVLT scores over time. 
 Aim 3:  To evaluate the association of time-varying antihypertensive treatment 
with incidence of dementia/CIND over 6 years of follow-up among older Mexican 
American hypertensive patients*. 
 Hypothesis:  Hypertensive patients receiving antihypertensive therapy over time 
have a lower incidence of dementia/CIND, compared to untreated hypertensive patients.   
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 * Hypertensive is defined as a systolic blood pressure >=140 mm Hg, or diastolic 
blood pressure >=90 mmHg, or evidence of treatment with any antihypertensive 
medication during the study period. 
1.2 Background  
1.2.1. Blood Pressure, Pulse Pressure, and Hypertension 
 Blood pressure is determined by cardiac output and peripheral vascular resistance.  
Systolic blood pressure, which is the peak pressure in the arteries, represents the ejection 
of blood into the aorta during ventricular systole (57).  It is largely determined by stroke 
volume, the elastic properties of aorta, and the velocity of ejection.  Diastolic blood 
pressure refers to the lowest pressure in the arterial system during diastole.  Diastolic 
blood pressure rises when peripheral vascular resistance increases (57).  Blood pressure 
changes with age.  Although the precise mechanism is not understood, the contributing 
factors of aging to increased blood pressure may include arterial stiffness, atherosclerosis, 
decreased functional efficiency of the heart, age-related changes in hormone profiles, and 
salt-sensitivity among older people etc.   In some non-industrialized countries, blood 
pressure is less likely to increase as people age. This difference may be explained by 
differences in diet and stress, among other things (58).   
 Burt et al. indicate that the relation between blood pressure and age is rather 
complex:  Systolic blood pressure increases with age for men and women, while diastolic 
blood pressure rises up to the age of 50-59 years and then begins to decline thereafter for 
both genders (Figure 1.1, 59).  Thus, the difference between systolic and diastolic blood 
pressure (defined as pulse pressure), increases steeply with age in the elderly population.  
Increasing evidence suggests that high pulse pressure in the elderly is a marker of 
increased artery stiffness and widespread atherosclerosis (20-21, 60-61).  Elevated pulse 
pressure is also recognized as an enhanced risk for cardiovascular events (2)  
 Hypertension, defined by American Heart Association, refers to blood pressure 
reading of >=140 mm Hg systolic and/or >=90 mm Hg diastolic or any treatment for 
hypertension (57, 59).  For people who are not taking antihypertensive medication, a 
blood pressure reading of <120 mm Hg systolic and <80 mm Hg diastolic is categorized 
as “normal” whereas a blood pressure reading of 120-139 mm Hg systolic and/or 80-89 
mm Hg diastolic is categorized as “pre-hypertension” (57, 59).  The classification of 
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hypertension for those who are not on antihypertensive treatment consists of two stages:  
stage 1: blood pressure reading of 140-159 mm Hg systolic and/or 90-99 mm Hg 
diastolic; and stage 2: blood pressure reading of >=160 mm Hg systolic and/or >=100 
mm Hg diastolic (57, 59).  Prevalence of systolic hypertension is directly proportional to 
advancing age (2). It is estimated that more than half of Americans over age 65 years had 
isolated systolic or combined systolic-diastolic hypertension while fewer than 10% of 
individuals in this age group had diastolic hypertension in 2005 (2).   Hypertension is a 
well-known independent risk factor for cardiovascular disease, stroke, and renal failure 
(2). 
1.2.2. Antihypertensive Treatment 
 Several antihypertensive agents are available for treating high blood pressure.   
The National High Blood Pressure Education Program (NHBPEP) recommended that 
most patients should use thiazide-type diuretics as their initial therapy for high blood 
pressure (62).  Other first line treatments may include other diuretics, ACEs, ARBs, ß-
blockers, calcium channel blockers, or combination (2, 62).  Randomized trials have 
shown that blood pressure lowering produces significant reductions in stroke and 
cardiovascular risk (36).   It has been reported that a decrease of 10-mm Hg in systolic 
blood pressure or 5-mm Hg in diastolic blood pressure may lead to a risk reduction of 
50% to 60% of stroke death and 40% to 50% of death due to cardiovascular disease or 
other vascular causes (63). 
 The basic pharmacological mechanisms of the commonly used antihypertensive 
drug classes are briefly summarized as follows (64): Thiazide-type diuretics, acting on 
late distal tubule of kidney, help body get rid of extra sodium and fluid.  As blood vessels 
hold less fluid, the volume of blood circulating through the body decreases, which lowers 
blood pressure.  Angiotensin-converting enzyme (ACE) inhibitors lower blood pressure 
by blocking the production of angiotensin II, a chemical that constricts blood vessels, 
which in turn makes it easier for blood to flow through the vessels.  By blocking the 
action of angiotensin II, Angiotensin II receptor blockers (ARBs) relax and widen blood 
vessels, which lowers blood pressure.  Both ACE inhibitor and ARBs also increase the 
release of sodium and water into the urine, which also lowers blood pressure.  Beta 
blockers block the effects of adrenaline (or hormone epinephrine) and lower the amount 
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of blood the heart pumps out with each beat, which in turn reduces blood pressure.  Beta 
blockers also help improve blood flow by relaxing and widening blood vessels.   Calcium 
channel blockers, by blocking calcium from entering cells of the heart and blood vessel 
walls, prevent blood vessels from constricting, which lowers blood pressure.     
1.2.3. Cognitive Decline 
 Cognition refers to a range of complex functions of the human mind including 
learning, concentrating, thinking, perceiving, reasoning, organizing, remembering, and 
using language, etc (65). Cognitive decline can be aging-related or disease-related.  In the 
National Health and Retirement Study, Plassman et al. found that about 22% of 
participants aged 71 and over had cognitive impairment that did not reach the threshold 
for dementia. They estimated that 5.4 million elderly aged 71 and over in the US in 2002 
had cognitive impairment without dementia (66).  In a study examining the relationship 
of mild cognitive impairment in different cognitive domains and incident Alzheimer’s 
disease, Aggarwal et al. reported that episodic memory impairment is associated with a 
substantial and persistent elevation in risk of developing Alzheimer’s disease compared 
to impairment in other cognitive systems such as semantic memory, working memory, 
perceptual memory, and visuospatial ability (67). 
 The 3MSE and SEVLT are two validated cognitive exams widely used to screen 
for cognitive impairment or dementia (68-69).  The 3MSE is a measure of global 
cognitive function that covers a broad range of cognitive abilities including episodic 
memory, semantic memory, working memory, perceptual memory, and visuospatial 
ability.  This 100 point test also includes orientation to time and space, registration, 
attention and concentration, recall and delayed recall, verbal fluency and abstract verbal 
reasoning, visual construction etc. (68).   The SEVLT is a delayed word list recall test 
with five 15-word trials (69) interrupted by a distracter list.  As a test of short term verbal 
recall, it consists of five semantic categories with examples of vegetables, drinks, kitchen 
utensils, reading materials, and fruit (69).   The test score is usually computed as the total 
number of words recalled after the distracter list.   
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1.2.4. Dementia 
 Dementia is characterized by a range of impairment in intellectual and mental 
abilities that include progressive decline in memory, spatial disorientation and other 
cognitive abilities (70-72).  Dementia has become increasingly prevalent as the 
population ages.   
 The most common form of dementia is Alzheimer’s disease (AD), accounting for 
50% to 70% of all cases (70-71, 73-74).  Clinical characteristics of AD include memory 
loss and cognitive impairment, confusion, mood alterations, and language deterioration.  
The presence of neuritic plaques and neurofibrillary tangles is the hallmark of 
neuropathology of AD (75).  β-amyloid peptide aggregates in the brain to form 
extracellular plaques, while tau protein becomes abnormally hyperphosphorylated and 
aggregates to form intracellular tangles.   Both plaques and tangles are present mainly in 
brain regions involved in learning and memory and emotional behaviours, such as the 
entorhinal cortex, hippocampus, basal forebrain and amygdale (76).  These regions are 
atrophied as a result of degeneration of synapses and death of neurons. 
 The second most common form of dementia is vascular dementia (VaD), 
accounting for about 15%-25% of all cases (70). VaD may result from small and large 
brain infarcts (eg, strokes), or from subclinical brain pathology such as diffuse subcortical 
white matter disease (77-78).  The primary etiologic element in VaD is ischemia, but the 
subsequent dementia progression involves a neurodegenerative process very similar to 
that seen in AD (76, 79) 
 AD and VaD often coexist and share many risk factors and clinical features (71, 
79).  For example, studies suggest that the apolipoprotein E4 allele, which is a risk factor 
for AD, is also associated with VaD; while hypertension, which is a risk factor for VaD, 
is also associated with AD (80-82).   This is termed ‘mixed dementia’.  
Neuropathological studies reported that coexisting vascular pathology occurs in 24%-
28% of AD cases (82). Other, less common, forms of dementia include dementia with 
Lewy Bodies, Pick’s Disease etc.  There are some relatively rare forms of dementia that 
are a result of infectious diseases and vitamin B12 deficiency. 
 Diagnostic and Statistical Manual of Mental Disorder, 4th edition (DSM-IV) 
criteria are used to diagnose dementia (83).  Briefly, the diagnostic criteria include: (i) the 
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development of multiple cognitive deficits should be manifested by both memory 
impairment and at least one of the following: aphasia, apraxia, agnosia, disturbances in 
executive functioning; (ii) the cognitive impairments must be severe enough to cause 
impairment in social and occupational functioning; (iii) the decline must represent a 
decline from a previously higher level of functioning; and (iv) the diagnosis of dementia 
should not be made if the cognitive deficits occur exclusively during the course of a 
delirium.  
 Epidemiological studies have classified participants in aging and dementia studies 
into 3 groups: demented, not demented, and CIND (55, 84).  CIND is a clinical syndrome 
consisting of measurable or evident decline in memory or other cognitive abilities with 
little effect on day-to-day functioning that does not meet the criteria for dementia as 
defined by Diagnostic and Statistical Manual of Mental Disorder, 4th edition (85).  CIND 
is diagnosed if the subject does not meet DSM-IV criteria for dementia but has clinically 
significant impairment in more than one cognitive domain (56). 
1.3 Biological Plausibility 
1.3.1 Hypertension, Stroke and Cognitive Impairment 
 Hypertension increases vascular wall tension by decreasing the elasticity of 
vessels, increasing resistance, and reducing responsiveness to changes in tissue demand 
(5-7). This pathological process contributes to atherosclerosis.  Several studies have 
reported that atherosclerosis is associated with cognitive impairment and subsequent AD 
and VaD (8).  There are several possible mechanisms by which hypertension might 
directly lead to cognitive impairment: (i) Ischemic stroke resulting from hypertension 
increases the risk of dementia (8-9); (ii) Hypertension may cause cerebrovascular 
damage, such as white matter lesions and multiple small infarcts (10) which contribute to 
cognitive impairment and dementia, in particular (but not only) VaD (11); (iii) Chronic 
hypertension leads to vessel wall pathology such as atherosclerosis and arteriolosclerosis, 
which further induces an insufficient cerebral blood flow and ischemia (12-13).  These 
pathological vessel changes are associated with cognitive dysfunction (12); (iv) 
Endothelia dysfunction and NO deficiency induced by oxidative stress and inflammatory 
responses due to longstanding hypertension are involved with the mechanisms of 
vascular disorders and AD (86-88).  .  In addition, neuro-pathological studies suggest that 
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persons with hypertension have increased neurofibrillary tangles and brain atrophy, 
linking directly the blood pressure and AD (14-15). 
 There is increasing evidence that stroke is a strong risk factor for AD, vascular 
and mixed (AD and VaD) forms of dementia (14, 37-44).  Studies of the risk factors for 
stroke have shown that hypertension is a leading contributor to stroke and that the level 
of blood pressure is directly associated with the risk of stroke (89).  People who have 
hypertension are 4 to 6 times more likely to have stroke (90).  Over time, atherosclerosis 
and hardening of the large arteries induced by hypertension would lead to blockage and 
weakening of the walls of small blood vessels in the brain, causing ischemic stroke due to 
clogging of blood vessels, and/or hemorrhagic stroke due to rupture of blood vessels in 
the brain. 
1.3.2 Low Blood Pressure and Cognitive Impairment 
 Studies have shown that cerebral hypo-perfusion due to lower blood pressure, 
particularly low diastolic blood pressure in late life, may also play a role in the 
development of cerebrovascular insufficiency (17-18, 20).  Evidence indicates that 
cerebral hypoperfusion appears to precede the neurodegenerative pathological changes 
(14), thus, it is likely that low blood pressure may initiate or accelerate disease processes 
leading to AD and dementia (14, 17, 91).  Alternatively, studies suggest that low diastolic 
blood pressure may be an indicator of increased large arterial stiffness and widespread 
atherosclerosis in elderly people (20-21, 92).  Low diastolic blood pressure resulted from 
the vessel wall pathology or decrease in cerebral blood flow may give rise to ischemic 
hypoxia that is linked with cognitive decline and dementia in very elderly populations 
(31).  
1.3.3 Pulse Pressure and Cognitive Impairment 
 Pulse pressure rises steeply after approximately 60 years of age (59).  It is 
positively associated with arterial stiffness and atherosclerosis (20-21, 60-61, 93), and 
therefore, it has been linked to an increased risk of cardiovascular diseases including 
stroke (94-98), which are also risk factors for cognitive dysfunction and dementia (99-
102).  Oxidative stress and inflammatory responses induced by arterial stiffness are 
involved with the mechanisms of vascular disorders and AD (87-88).  In addition, 
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clinically silent cerebrovascular lesions, cerebral microcirculation damage, cerebral 
hypoperfusion, and other vessel pathology resulting from higher pulse pressure appear to 
predispose individuals to the development of cognitive impairment and subsequent 
dementia (34-35, 88, 103).  Lower pulse pressure most likely contributes to diminished 
cognitive function and dementia through cerebral hypofusion (35).  
1.3.4 Antihypertensive Treatment and Dementia 
 The precise mechanisms for potential effects of antihypertensive therapy on 
dementia are not fully understood.  Through blood pressure reduction, antihypertensive 
drugs may lower the risk of progressing into dementia by correcting the underlying blood 
pressure related mechanisms, such as hypertension induced stroke, cerebrovascular 
damage, and cerebral hypofusion, and the atherosclerotic process.  The non-blood 
pressure related effects are mediated by mechanisms other than blood pressure reduction.  
For example, calcium channel blockers prevent calcium influx that may cause neuronal 
death due to release of intracellular enzymes (47). 
1.4 Epidemiological and Clinical Studies 
1.4.1 Blood Pressure and Cognitive Decline 
 Longitudinal studies have been conducted to examine the relationship between 
blood pressure in midlife and/or late life and decline in cognitive function.  The results of 
these studies are mixed and depend on the age when the blood pressure is measured, 
length and frequency of follow-up, study population, method of blood pressure 
collection, and outcome assessments used.     
 Longitudinal observational studies that investigated midlife blood pressure in 
relation to late-life cognition decline consistently reported that high blood pressure in 
midlife, especially high systolic blood pressure, is associated with poor cognitive 
performance (35, 104-111).   These studies often had 20-30 years of follow-up and most 
concluded that untreated high blood pressure in midlife was a strong risk factor of 
cognitive impairment in later life (104-106, 109, 112).   
 Epidemiological studies investigating the relationship between late-life blood 
pressure and cognitive decline, however, did not consistently support the notion that 
elevated blood pressure in later life was related to decline in cognition (16, 19, 22-32).  
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Three studies reported no association between blood pressure and cognitive decline (19, 
26-27); five studies reported an inverse association between blood pressure and cognitive 
performance (28-32); four studies reported a U-shaped relation of systolic or diastolic 
blood pressure to cognitive decline (16, 23-25); and one study reported that low systolic 
blood pressure was associated with cognitive deficit (22).   
 Among the studies reporting no association, Hebert’s biracial longitudinal 
population study suggested that prevalent use of hypertensive medication at baseline 
(50%) could be a contributing factor to the null effect (19); Tervo et al in their three-year 
follow-up study of cognitively healthy elderly subjects found that medicated hypertension 
was related to decline in cognitive performance as treated hypertension might indicate 
more severe hypertension (26).  Among the studies reporting an inverse association, most 
had a longer follow-up (e.g. >=5 years), or used the higher cut-off of blood pressure 
measurement (e.g. systolic blood pressure >=160 mmHg) than those studies reporting 
null results.  In particular, the Cardiovascular Heart Study found an association between 
higher systolic blood pressure and longitudinal decline in cognitive performance (29), 
and Population Study in Kuopio demonstrated that untreated hypertensive patients were 
at the highest risk for cognitive decline over 4 years (28).  Of the four studies reporting a 
U shaped relation, the Baltimore Longitudinal Study of Aging had more than two follow-
up visits and found that both low and high systolic and diastolic blood pressure were a 
threat to cognitive function (16).  Both Kungsholmen Project and Baltimore Longitudinal 
Study of Aging revealed that the effects of high systolic blood pressure on cognitive 
decline were strongest among people who did not taking hypertensive medication (16, 
23).         
1.4.2 Pulse Pressure and Cognitive Decline  
 Few population-based studies have examined the relationship between pulse 
pressure in late life and decline in cognitive function.  As far as we are aware, only one 
study has specifically investigated this relationship despite the theoretic reasons for its 
importance (34):  Waldstein reported that higher pulse pressure was associated with 
accelerated decline in cognitive function, in particular, learning, memory, and 
concentration, over time.  In addition, three longitudinal studies examined the association 
of pulse pressure in mid/late life and dementia or AD and the findings were inconclusive:  
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In the Kungsholmen project, Qiu et al reported a U-shape relationship between level of 
pulse pressure and risk of AD and dementia in those aged 75 years and older (35).  A 
community-based cohort study, however, found marginal evidence for the association 
between high pulse pressure and an increased risk of AD in adults aged 65 years and 
older (45).  One study of midlife pulse pressure and incidence of dementia indicated that 
pulse pressure was not independently associated with dementia incidence (113).   
1.4.3 Antihypertensive Treatment and Dementia 
 The seven longitudinal observational studies that have investigated the 
relationship between antihypertensive treatment and development of cognitive 
impairment/dementia in elderly population have reported mixed results (45-51):  The 
East Boston cohort study (46) and the Canadian Study of Health and Aging (45) reported 
no association between antihypertensive therapy use and AD, and the Baltimore 
Longitudinal Study of Aging found no association between the use of calcium channel 
blockers and AD (47).  Among four studies reporting protective effects of 
antihypertensive medications (48-51), the Kungsholmen project showed that using 
diuretics, the most commonly used therapy, was associated with a significant reduction of 
dementia risk (48).  The results from the Cache County Study also suggested beneficial 
effects of diuretic use on AD incidence (51).  The Rotterdam study (49) demonstrated a 
substantial effect of antihypertensive therapy in reducing the risk of dementia and VaD, 
though the results observed in AD patients did not reach statistical significance.  While 
the majority of studies focused on a predominantly Caucasian population, Murray et al. 
revealed protective effects of antihypertensive drugs on cognitive function in the first and 
largest longitudinal study focusing on older African Americans (50).   
 Four large randomized placebo-controlled clinical trials which evaluated the 
effects of antihypertensive treatment on development of dementia showed inconsistent 
results (114-118):  The Systolic Hypertension in the Elderly Program (SHEP) found no 
significant reduction of dementia risk in the group receiving active treatment of diuretics 
and/orβ -blocker compared to placebo (114).  However, a re-analysis of the data 
indicated that differential drop-outs may have biased the cognitive assessment and 
potentially obscured a protective effect of treatment on dementia and cognitive decline 
(119).  In the Systolic Hypertension in Europe (SYST-EUR) trail, active treatment was a 
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calcium channel blocker (nitrendipine), combined with an ACE inhibitor (enalapril) 
and/or a diuretic (hydrochlorothiazide) if necessary (115-116).  This trial demonstrated 
that active treatment reduced the development of dementia in elderly people with isolated 
systolic hypertension by 50% over 2 years (115).  The extended trial, in which all 
participants from the initial trial continued on active treatment for another 2 years, 
confirmed the original results that long-term antihypertensive therapy reduced the 
incidence of dementia by 55% (116).  In the Perindopril Protection Against Recurrent 
Stroke Study (PROGRESS), participants were assigned to either active treatment 
(consisting of ACE inhibitor (perindopril) for all participants, or combined with a 
diuretics (inadpmide)) or a matching placebo (118).  After 4 years of follow up, the risk 
of dementia was reduced by 34% in patients with recurrent stroke.  However, no 
significant effect from the active treatment on the overall risk of dementia was observed.  
The Study on Cognition and Prognosis in the Elderly (SCOPE) evaluated the role of 
antihypertensive therapy in preventing cognitive decline and subsequent dementia among 
the elderly with mild and moderately raised blood pressure (117).  The active treatment 
consisted of ARB candesartan with open-label active antihypertensive therapy added, as 
needed.  After 3.7 years of follow up, no significant difference in dementia incidence and 
cognitive decline between active treated group and placebo group was observed.  This 
lack of protective effect may be partially explained by the fact that most patients in the 
placebo group were treated with other antihypertensive drugs for ethical reasons.   In 
addition, two clinical trials examining the effect of antihypertensive therapy and 
cognitive decline also offered mixed results:  The Heart Outcomes Prevention Evaluation 
(HOPE) study, reported a 41% reduction of cognitive decline related to stroke, using 
ACE inhibitors (120) while Medical Research Council's treatment trial (MRC) found no 
significant risk reduction in dementia or cognitive decline in the active treatment group 
receiving diuretics and/or β -blocker compared to the placebo group (121). 
 While some longitudinal studies have suggested protective effect of 
antihypertensive treatment on development of dementia or Alzheimer’s disease, evidence 
from randomized clinical trials is still limited.  Factors that may have contributed to the 
varied results in both types of studies may include antihypertensive agents, study design, 
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length and frequency of follow-up, study population, sample size, and duration of 
treatment.   
1.5 Methods  
1.5.1 Study Population  
  Sacramento Area Latino Study of Aging (SALSA) is a longitudinal prospective 
cohort study designed to examine whether risk factors (diabetes, hypertension, smoking 
and obesity) increase the risk of dementia, memory loss, functional impairment, and 
decline in cognitive and physical functioning (55). A detailed description of sampling and 
recruitment in the SALSA study has been described elsewhere (55).  The eligible 
participants were community-dwelling, non-institutionalized Latinos aged 60 years and 
older in 1998-1999, who lived in the Sacramento area and San Joaquin Valley in 
California. At baseline, 1789 people were enrolled in the study, and followed from 
1998/99 through 2007.  The average length of follow-up was 6.11 years and the 
maximum length was 9 years.   Among the 1789 SALSA participants, 115 had dementia 
or “cognitively impaired not demented” (CIND) at baseline.  The analytical sample 
included 1674 subjects who had no prevalent dementia or CIND at baseline and had 
available data for at least baseline measurements.   
1.5.2 Overview of Analytical Method and Models in the Study   
 The conceptual models for the 3 aims are presented in Figures 1.2, 1.3, and 1.4.  
An exposure variable, an outcome variable, potential confounding variables, and effect 
modifiers for each aim are specified in the conceptual models.   
  For aim 1 and 2, linear regression models with mixed (fixed and random) effects 
were used to assess respectively the associations of systolic blood pressure/diastolic 
blood pressure, or pulse pressure with decline in cognitive function.  Such models 
allowed for the examination of cross-sectional (across all visits or at a given visit) and 
longitudinal (change over time) relations of an exposure variable (systolic blood pressure, 
diastolic blood pressure, or pulse pressure) to an outcome variable (errors in 3MSE or 
SEVLT score).  Systolic blood pressure, diastolic blood pressure, or pulse pressure was 
used as a continuous exposure variable in each of the models while 3MSE or SEVLT 
performance was used as a continuous outcome variable in each model.   
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 For aim 3, Cox proportional hazard models were applied to test the association 
between antihypertensive treatment use and risk of dementia/CIND.  The use of 
hypertension medication was included in the COX model as a time varying exposure 
variable and lagging analysis was performed to reduce ambiguity in the causal ordering 
(122):  time-varying hypertension medication use was measured at the prior visit when 
dementia/CIND was diagnosed or when last visit was available.  It was counted up to and 
including Visit 5 (out of 6 follow-up visits) with a lag value of hypertension medication 
use.    
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1.6 Tables and Figures  
 





Figure 1.2 Conceptual Causal Model of Systolic or Diastolic Blood Pressure and 
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Figure 1.3 Conceptual Causal Model of Pulse Pressure and Cognitive Decline 




Figure 1.4 Conceptual Causal Model of Antihypertensive Treatment and Incidence 
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1.7 Appendices 
Appendix 1.1.  Review of prospective cohort studies of late-life blood pressure in 
relation to cognitive function change 
 
Author/date Study Sample 
size/age of 
l
BP measure Outcome 
measure
Method Result
Guo et al, 1997
Kungsholmen 
Project,Sweden
1736 people, age 
>=75 years, follow-up 
3 years
BP measurements in 
sitting position; if first 
measurement was 
abnormal, use the 





SBP<=130 mmHg (p<0.05);  SBP >=180 
mm HG and DBP >=95 mmHg in untreated 
group is a threat, though p>0.05
Glynn et al, 1999
East Boston cohort 
study, USA
3657 people, age 
>=65 years,follow-up 9 
years








error rate of cognitive test associated with 
BL SBP <130mmHg: 9% (1%, 17%),, with 
BL SBP >=160 mmHG 7% (0%, 15%)
Tzourio et al, 1999
Epidemiology of 
Vascular Aging Study, 
France
1172 people; age 
59–71 years, follow-up 
4 years
average of two BP 
measurements MMSE score logistic regression
Association of high BP (SPB >=160 mm 
Hg, DBP >=95 mm Hg) at baseline and 






recipients, age  65 
years, followed up to 7 
years
average of two BP 
measurements  in 
sitting position; 
3 MSE, digit 
symbol subtest GEE
Systolic blood pressure (>158 mm Hg) was 
associated with decline of 3 MSE score 




Studies of the Elderly, 
USA
3202 people ,age  65 
years, follow-up 3 
years
Two- three BP 
measurements in 
sitting position and 
use average the two 
closest reading
mental status 
questionnaire multiple regression 
U-shape association of SBP (<110 mm Hg, 
>165 mm Hg) and cognitive decline for 




1423 people, age 
55–88 years, follow-up 
4–6 years
average of two BP 
measurements  in 
sitting position; 
Neuropsychologi
cal test battery multiple regression
for men only (hypertension >=140 mm Hg, 
high DBP >=90 mm Hg), p<0.05
Reinprecht et al , 
2003 Men born in 1914 study
186 men, age 68,








DBP (tertilles) at age 68 years was 
inversely related toVerbal. Spatial, and 
speed performance at age 81
Piguet et al,  2003
Sydney Older Persons 
Study, Australia
377 people, age >=75; 







clinically diagnosed hypertension was 
related to greater decline in MMSE score 
over 6 years
Hebert et al, 2004
Chicago Health and 
Aging Project, USA
4284 people, age  65 
years, follow-up visit at 
3 year and 6 year




recall;  the 
Symbol
Digit Modalities 
Test, MMSE linear mixed model
no effect annual change of  SBP (p=0.3) or 
annual change of DBP (p=0.7) on cognitive 
decline
there is nonlinear association of annual 
change of DBP with cognitive decline 
(p=0.03) 
Tervo et al, 2004
Population study in 
Kuopio, Finland
806 people, age 
60–76 years,follow-up 
3 years ( 1 follow-up 
visit)
measured at baseline 
only cognitive tests logistic regression
no effect of hypertension (DBP >=95 or 
SBP >=160):  0.91 (0.49 - 1.69):
medicated hypertension:  1.86 (1.05 - 3.29)
Solfrizzi et al, 2004
Longitudinal Study on 
Aging, Italy
1445 people, age 




average of last two of 
three BP 
measurements cognitive tests Poisson regression
hypertension (SBP >=140 or DBP >=90) 
1.44 (0.91-2.35)
Waldstein et al, 
2005
Baltimore Longitudinal 
Study of Aging, USA
847 people; age 
60–96 years,followed 
up to 11 years (1-7 
visist)




cal tests linear mixed model
U shape DBP association with cognitive 
decline (p <0.05)
higher SBP in older individuals (age 80 
above) is associated with cognitive decline: 
p<0.05
Nilsson et al, 2007
Longitudinal study of 
oldest, Sweden
599 people, age 80-
95; follow-up: 4 years
measured after 
recumbent rest for 
>=3 min. MMSE score
logistic regression;
linear regression
low SBP is associated with cognitive deficit, 
beta (LR)=0.986 (0.976, 0.995)  
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Appendix: 1.2.  Review of prospective cohort studies of late-life pulse pressure in 
relation to cognitive function change 
 
Author/date Study Sample size/age 
of sample
Follow-up
BP measure Outcome 
measure
Method Result
Qiu et  al, 2003
Kungsholmen 
Project,Sweden
1270 dementia free 
subjects, age >=75 
years, mean follow-up 
4.7 years
BP measurements in 
sitting position; mean 








U shape PP association with AD and all 
dementia: people with high PP (>84) had 
RR=1.4(1.0, 2.0) for AD and RR=1.3 (0.9, 
1.7) for dementia; people with low PP 
(<70)  had RR=1.7 (1.2, 2.3) for AD and 
RR=1.4 (1.0, 1.9) for dementia, compared 
with those median tertile PP (70-84)
Morris et al, 
2001
East Boston Study 634 subjects free-AD; 
age >=65; follow-up 4 
years




Logistic regression Marginal association with AD: 
OR=0.85/10 mm Hg incraese in PP, 0.70-
1.02) 




Study of Aging, 
USA
1749 people; age>=60; 
followed up to 14 
years (1-8 visist)




cal tests linear mixed model
High PP was associated with longitudinal 
decline of several cognitive function tests 
(p<0.05) such as verbal learning, nonverbal 
memory, working memory et al. 
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Appendix 1.3.  Review of prospective cohort studies of effect of antihypertensive 











Guo et al, 
1999









Risk reduction in dementia 
or AD using diuretics 












No effect of 
antihypertensive on risk of 




free subjects (118 
incident cases); 
aged >=55










Risk reduction in VaD 
HR=0.3 (0.11, 0.99) and 
dementia RR=0.67 (0.45, 







incident AD cases); 
age>=65







No effect of 
antihypertensive agents on 
AD:  OR=0.91 (0.64, 1.30)
Murray et 
al. 20002




5 years Dementia and 
cognitive 
impairment: DSM 






Risk reduction in cognitive 
impairment using any AHT:  
OR=0.62 (0.45, 0.84)
Yasar et al. 
2005




Up to 19 years AD: DSM III-R CCB Cox proportional 
model 
No effect of CCB on risk of 
AD: HR=0.30 (0.07, 1.25) 
Khachaturi
an et al., 
2006
3308 subjects (104 
incident AD); age 
>=65










Risk reduction in AD using 
any AHT HR=0.64 (0.41, 
0.98); using diuretics 
HR=0.57 (0.33, 0.94); using 
beta blockers HR=0.53 
(0.22, 1.09); no effect of 
CCB:  HR=0.86 (0.45, 1.53)  
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Appendix 1.4.  Review of clinical studies of effect of antihypertensive treatment on 
dementia 
 













n1=3051 in treated group 
and n0=3054 in placebo 
group;
mean age=64; subjects with 
prior stroke or transient 
ischemic attack;  







Perindopril (ACE); or 




34% risk reduction of dementia 
(3%, 55%) and 45% risk 
reduction of cognitive decline 
(21%, 61%) in recurrent stroke 
patients






n1=4645 in treated group 
and n0=4652 in placebo 
group; 
age >=55 with prior history 







Ramipril (ACE) Cox regression 41% reduction of cognitive 










n1=2365 in treated group 
and n0=2371 in placebo 
group; 
age >=60 and and SBP (160-
219 mm Hg) and DBP<=90; 













no significant risk reduction in 
dementia in the group receiving 
active treatment of diuretics 
and/or beta-blockers compared to 
placebo






n1=633 diuretcs group, 
n2=640 bete blocker group; 
n0=1311 in placebo group; 
age (65-74) and SBP (160-
209 mm Hg) and DBP < 
115 mm Hg;





PALT, and Trail 





ANOVA no significant risk reduction in 
cognitive decline in the group 
receiving active treatment of 
diuretics and/or beta-blockers 
compared to placebo






n1=2885 in treated group 
and n0=2737 in placebo 
group; 
age >=60 and SBP (160-
219 mm Hg) and DBP<=95; 
median follow-up 2 years
Dementia (DSM 




combined with an ACE 
inhibitor (enalapril) 




estimates and log 
rank test; COX 
regression
reduced dementia in elderly 
people with isolated systolic 
hypertension by 50% (p<0.05); 
on average, MMSE score did not 
change in either group 







n1=1485 in treated group 
and n0=1417 in placebo 
group;  
age >=60 and SBP (160-
219 mm Hg) and DBP<=95;
median follow-up 3.9 years 
Dementia (DSM 




combined with an ACE 
inhibitor (enalapril) 




estimates and log 
rank test; COX 
regression
reduced dementia in elderly 
people with isolated systolic 
hypertension by 55% (p<0.001) 
Lithell et al., 
2003
The Study on 
Cognition and 
Prognosis in the 
Elderly (SCOPE) 
n1=2477 in treated group 
and n0=2460 in placebo 
group;
age (70-89) and SBP (160-
179 mmHg) and/or DBP 
(90-99 mmHg);






assessment and  
adjudication)
ARB candesartan 
active AHT was 
extensively used in the 
control group (84%)
log rank test; 
ANCOVA
The proportion of patients who 
had a significant cognitive 
decline or development dementia 
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CHAPTER 2 
BLOOD PRESSURE AND CHANGE IN COGNITIVE FUNCTION IN ELDERLY 
MEXICAN AMERICANS: A POPULATION-BASED COHORT STUDY 
2.1 Abstract 
OBJECTIVE:  The association between blood pressure in late life and cognitive decline 
has not been conclusively established, and existing studies have not included minority 
populations, such as non-White Hispanic Americans. The objective of this study was to 
evaluate the relationship between baseline and time-dependent systolic and diastolic 
blood pressure and decline in cognitive function over 6 years of follow-up among older 
Mexican Americans living in the Sacramento, California area. 
RESEARCH DESIGN AND METHODS: The Sacramento Area Latino Study of Aging 
(SALSA) was a longitudinal prospective cohort study with an average length of follow-
up of 6.11 years.  Participants were 1789 community-dwelling, non-institutionalized 
Latinos aged 60 years and older in 1998-99.  A total of 1674 individuals who had no 
prevalent dementia and were not “cognitively impaired not demented” (CIND) at 
baseline and had available data for at least baseline measurements were included in the 
study.  Cognitive assessments using “Modified Mini-Mental State Examination (3MSE)” 
and “Spanish English Verbal Learning Test (SEVLT)”, and measurements of systolic and 
diastolic blood pressure were performed at baseline and at each of the 6 follow-up visits.  
Linear regression models with mixed (fixed and random) effects were used to assess 
respectively, the association between systolic blood pressure (SBP), or diastolic blood 
pressure (DBP) and cognitive function over time.   
RESULTS:  Longitudinal findings indicated that (i) higher baseline SBP was associated 
with longitudinal decline in performance on 3MSE and SEVLT: an annual increase of 
error in 3MSE was 2% (0.8%, 2.7%) and an annual decline in SEVLT score was -0.04 (-
0.07, 0) points, for every 20 mm Hg increase of SBP at baseline; (ii) higher concurrent 
SBP was related to longitudinal decline in 3MSE performance among untreated 
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participants: an annual increase of error in 3MSE was 2% (0.6%, 3.2%) for every 20 
mmHg increase of concurrent SBP (iii) the annual decline was more pronounced among 
untreated individuals with uncontrolled SBP (>=140 mmHg):  an annual increase of error 
in 3MSE was 4% (1%, 7%) for every 20 mmHg increase of concurrent SBP;  (iv) higher 
concurrent DBP was associated with longitudinal improvement in performance on both 
tests and among those with low DBP (<=60 mmHg), the annual increase in SEVLT 
scores was more pronounced:  an annual decline of error in 3MSE was -1% (-1.5%, 1%), 
an annual increase of SEVLT score was 0.06 (0.03, 0.09) points, and an annual increases 
of SEVLT scores were 0.4 (0.04, 0.67) points among those with DBP <=60 mmHg, for 
every 11 mmHg increase in concurrent DBP;  (iv) higher baseline DBP was associated 
with longitudinal improvement in SEVLT scores: an annual increase in SEVLT score 
was approximately 0.04 (0.01, 0.07) points, for every 11 mmHg increase of DBP at 
baseline.  In addition, cross-sectional findings (across all visits) indicated that higher 
concurrent SBP was associated with higher mean errors in 3MSE and lower mean scores 
in SEVLT: a mean error in 3MSE increased by 2% (1%, 3.2%) and a mean score in 
SEVLT declined by -0.1 (-0.16, -0.04) points, for every 20 mmHg increase of SBP.  
When treated at baseline, individuals with uncontrolled SBP had 7% (2%, 11%) more 
mean error in 3MSE as compared to those with controlled SBP.  All associations found in 
this study were fairly small in magnitude. 
CONCLUSION: Results of 6 years of follow-up data from the SALSA study 
demonstrated that higher SBP was associated with longitudinal decline in cognitive 
function after adjusting for potential confounding variables; untreated individuals with 
uncontrolled SBP were at highest risk of cognitive impairment.  In addition, higher DBP 
was associated with longitudinal improvement in cognitive function after adjusting for 
potential confounding variables. This longitudinal improvement was more pronounced 
among individuals with low DBP.  These results suggested that proper use of 
antihypertensive treatment to keep optimal level of SBP and DBP is important to 
preserve cognitive function in the elderly. 
2.2 Introduction 
 Hypertension is an important independent risk factor for cardiovascular disease, 
stroke, and renal failure (1).  However, the relationship between hypertension and 
32 
cognitive function is not well understood.  Seven studies that examined midlife blood 
pressure in relation to late-life cognitive decline consistently demonstrate that midlife 
high blood pressure, especially high SBP, is associated with poor cognitive performance 
(2-10).   At least 13 epidemiological studies have examined the association between late-
life blood pressure and cognitive decline.  However, they do not consistently support the 
finding that elevated blood pressure in later life is a risk factor for cognitive impairment 
(11-23).  Among these 13 studies, three studies reported no association between blood 
pressure in late life and cognitive decline (16-18); five studies found an inverse 
association between blood pressure in late life and cognitive performance (19-23); four 
studies showed a U-shaped relation of SBP or DBP to cognitive decline in elderly (11, 
13-15); and one study indicated that low SBP was associated with cognitive deficit in late 
life (12).   
The hypothesis of an association between blood pressure and cognitive function is 
best examined using longitudinal data, ideally with multiple follow up measurements of 
blood pressure and cognitive function (11, 14, 16).  The objective of this study was to 
evaluate the relationship between systolic and diastolic blood pressure and decline in 
cognitive function over 6 years of annual follow-up among older Mexican Americans 
living in the Sacramento, California area. To our knowledge, this study was the first to 
focus on older Mexican Americans, a rapidly growing ethnic population in US.   
 2.3 Methods 
Study population:  The Sacramento Area Latino Study of Aging (SALSA) was a 
prospective longitudinal cohort study designed to examine whether risk factors (diabetes, 
hypertension, smoking and obesity) increase the risk of dementia, memory loss, 
functional impairment, and decline in cognitive and physical functioning (24). A detailed 
description of sampling and recruitment in the SALSA study has been provided 
elsewhere (24).  Eligible individuals were community-dwelling, non-institutionalized 
Latinos aged 60 years and older in 1998, who lived in the Sacramento area and San 
Joaquin Valley in California. At baseline, 1789 people were enrolled in the study, and 
followed from 1998/99 through 2007.  The average length of follow-up was 6.11 years 
and the maximum length was 9 years.   Among the 1789 SALSA individuals, 115 had 
dementia or “cognitively impaired not demented” (CIND) at baseline and were excluded 
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from this analysis.  Thus, the analytical sample included 1674 subjects who had no 
evidence of dementia or CIND at baseline and had available data for at least baseline 
measurements.   
Data collection: All data for this study at baseline and at follow-up visits were 
collected by interviews and clinical assessments at home visits every 12-15 months from 
1998/99 through 2007.  To maintain contact and gather updated information about health 
status and medication use, a brief telephone interview was added midway between each 
home visit.   
Outcome measurement – 3MSE:   The Modified Mini-Mental State Examination 
(3MSE), a cognitive screening test, was performed for each participant at each home 
visit.  The 3MSE is a 100-point cognitive exam that measures global cognitive function 
by testing orientation to time and space, registration, attention and concentration, recall 
and delayed recall, verbal fluency and abstract verbal reasoning, visual construction, etc. 
(25).  Higher test scores indicate better global cognitive performance.  The test has been 
validated in Spanish and widely used as a screening instrument for Alzheimer's disease or 
dementia (12-13, 19, 26-29).  The cognitive assessment was performed at baseline and at 
each of the 6 follow-up visits. 
Outcome measurement - SEVLT:  The Spanish English Verbal Learning Test 
(SEVLT) is a delayed word list recall test with five 15-word trials (30) interrupted by a 
distracter list.  It measures short term verbal recall. The test consists of five semantic 
categories with examples of vegetables, drinks, kitchen utensils, reading materials, and 
fruit (30).  The test scores range from 0 to 15 with higher scores indicating better 
performance.  The cognitive assessment was performed for each participant at baseline, 
and at each of the 6 follow-up visits. 
Exposure measurement – SBP and DBP:  At each home visit, SBP and DBP were 
measured by trained staff using an automatic digital blood pressure monitor (OMRON 
MODEL: HEM-747 IC) which was calibrated biannually.  Two readings of sitting 
measurements after 5-minutes rest were taken at baseline and at each annual visit and the 
average of the two measurements was analyzed.  The clinical assessment of SBP and 
DBP was performed at baseline, and at each of the 6 follow-up visits. 
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Measurement of Covariates:  Eight baseline covariates were initially included in 
the analyses.  Age, measured in years, was calculated from date of birth and baseline 
visit; gender was collected at baseline; education, measured in years, was collected at the 
baseline visit; waist circumference, measured at the level of maximum indentation over 
the abdomen, when the participant bended to the side, was taken in centimeters at 
baseline and converted to inches; smoking status was assessed by asking each participant 
to select one of three responses that best described their smoking status at the baseline 
visit:  never smoker, former smoker, or current smoker;  history of stroke was determined 
by self-report of a physician’s diagnosis at the baseline visit;  history of heart disease was 
determined by self-report of a physician’s diagnosis at baseline by answering “yes” to the 
questions about myocardial infarction, angina pectoris, or congestive heart failure;  
diabetes was ascertained if a participant met the following 3 criteria at baseline:  fasting 
plasma glucose (FPG) level ≥126 mg/dL (7.0 mmol/L) (fasting was defined as no caloric 
intake for at least 8 hours), or use of an anti-diabetic medication, or self-report of a 
doctor’s diagnosis of diabetes. 
In addition, hypertension medication use at baseline and at each follow-up visit 
was included in the analyses as a potential modifier.   The use of all prescription drugs, 
including antihypertensive drugs, was ascertained at each participant’s home at baseline 
and at each follow up visit by direct inspection of all medications.  The medication 
information, including the medication code, dose, number of prescribed pills, and average 
number of pills taken was entered by trained personnel onto a collection form. This 
information was then updated by telephone every 6-8 months between home visits. 
Medication codes were assigned using the Centers for Disease Control (CDC) 
Ambulatory Care Drug Database System (31).  Antihypertensive drugs included all 
medications potentially used for lowering blood pressure.   
Statistical analyses:  Linear regression models with mixed (fixed and random) 
effects were used to assess respectively, the association between SBP or DBP and 
cognitive function.  Such models allowed for the examination of cross-sectional (across 
all visits or at a given visit) and longitudinal (change over time) relationship between 
exposure variable (SBP or DBP) and cognitive function.  The cross-sectional relationship 
were indicated by BP main effects or interactions between blood pressure and each of the 
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covariates, while the longitudinal relationship were represented by interactions between 
blood pressure and time interval (or three-way interaction of blood pressure, hypertensive 
medication use, and time interval).  The predictors of interest, such as SBP or DBP were 
entered into the models as fixed effects.  Random effects were modeled by taking into 
account the variability in initial level of 3MSE or SEVLT performance and rate of change 
between subjects.  The initial graphical analysis and univariate test indicated that 3MSE 
data were skewed since most individuals had high 3MSE scores at baseline.  In order to 
normalize the data, a natural log transformation of error in 3MSE (101-3MSE) was used 
as the dependent variable in all models.  An annual change in 3MSE error, given a 
standard deviation (SD) unit increase in BP, was calculated as follows: [(101-3MSE2) / 
(101-3MSE1)] = exp [ ß * SD] , where ß is coefficient of interaction between BP and 
time.   A preliminary graphic analysis and univariate test indicated that SEVLT data had 
a normal distribution and was directly used as the dependent variable in all models.      
Two sets of mixed models were applied to examine the association between 
systolic blood pressure or diastolic blood pressure and error in 3MSE, or SEVLT score:  
the first set was baseline models assessing the association of each baseline exposure 
variable and error in 3MSE or SEVLT score; and the second set was time dependent 
models assessing the association of each time-dependent exposure variable and error in 
3MSE, or SEVLT score.  For each set of models, both unadjusted and adjusted effects of 
the exposure variable were examined.   Prior knowledge of biological plausibility as well 
as the change-in-estimate criterion was applied to determine covariates to be included in 
the final models.  Six baseline covariates (age [years], gender, education [years], diabetes 
[yes/no], history of stroke [yes/no], and smoking status [current smoker/former 
smoker/never smoker]) were used for adjustment in the final models.   
Use of hypertension medication was examined at baseline or over time to assess 
whether it would moderate the longitudinal relationship between concurrent SBP and 
3MSE or SEVLT performance.  This was done by adding three-way interaction of 
medication use with SBP*time in the model.  Stratified analyses were performed if 
statistical interaction was present.  Tests for a nonlinear relationship between SBP or 
DBP and cognitive function were conducted by including squared blood pressure terms in 
the models.   
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All models were fitted using SAS PROC MIXED.  Only statistically significant 
interaction terms (p<0.05) were included in the final models. 
2.4 Results  
Demographic characteristics:   The characteristics of individuals at baseline are 
presented in Table 2.1.   The majority of individuals were female (58%), mean age was70 
years, and mean education was 7.3 years.  Current smokers comprised 11% of the study 
population.  Baseline prevalence of comorbidities included diabetes (32%), stroke (8%) 
and heart disease (14%). On average, SBP at baseline in the study population was 
relatively high (138 mmHg), approaching the upper end of the pre-hypertension range, 
while average DBP at baseline was normal (76 mmHg).  There was a high prevalence of 
hypertension at baseline (61%).  Although less than half of individuals used 
antihypertensive medication at baseline (42%), usage increased over time and reached 
52% at the 3rd visit and 70% at the 6th visit.  Most of individuals scored well in the 3MSE 
test at baseline with a median score of 89 out of 100.  Average score of SEVLT at 
baseline was 8.6 out of 15.  
Systolic Blood Pressure 
Baseline SBP and cognitive function tests:  Table 2.2 presents the relationship 
between baseline SBP and performance in cognitive function tests.  Baseline models 
indicated that unadjusted SBP at baseline was significantly associated with a higher mean 
error in 3MSE and lower mean score in SEVLT (model I and III).  For every standard 
deviation (SD=20 mmHg) increase of SBP at baseline, mean error in 3MSE increased by 
14%, while mean score in SEVLT decreased by 0.4 points.  The relationship between 
SBP to the actual 3MSE performance is presented in Figure 2.1.  Subjects with a lower 
initial level of 3MSE had a larger drop of 3MSE scores due to the increase in SBP at 
baseline.  There was a longitudinal relationship between baseline SBP and error in 3MSE 
and SEVLT score after adjusting for all covariates (model II and IV).  SBP at baseline 
was statistically significantly related to change in 3MSE and SEVLT performance over 
time:  an annual increase of error in 3MSE was approximately 2% and an annual decline 
in SEVLT score was approximately 0.04 points, for every 20 mm Hg increase of SBP at 
baseline.    
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Time-dependent SBP and cognitive function tests:  Table 2.3 presents the 
relationship between time-dependent SBP and performance in cognitive function tests.  
While unadjusted SBP was associated with lower mean score in SEVLT (model I), no 
association between unadjusted SBP and mean error in 3MSE was observed (model III).   
There was no longitudinal relationship between time-dependent SBP and performance in 
3MSE or SEVLT after adjusting for all covariates (Model II and IV).  Cross-sectional 
findings (across all 7 visits) revealed that adjusted SBP was marginally significantly 
associated with a higher mean error in 3MSE, and statistically significantly associated 
with a lower mean score in SEVLT:  for every one SD (20 mmHg) increase of SBP, a 
mean error in 3MSE increased by 2%, and mean score in SEVLT declined by 0.1 points.   
Moderation of hypertension medication to the association of SBP and cognitive 
function:  First, the results showed that the relationship between adjusted SBP and change 
in 3MSE error over time was dependent on concurrent hypertension medication use 
(Table 2.4).  Separate analyses by concurrent medication use indicated that adjusted SBP 
was statistically significantly related to change in 3MSE error among those who did not 
take hypertension medication over time: for every 20 mm Hg increase of concurrent SBP, 
the annual increase of error in 3MSE was approximately 2% among those non-medicated 
users.  Furthermore, among subjects with uncontrolled SBP (>=140 mm Hg) and not 
taking hypertension medication over time, the annual increase of error in 3MSE was 
approximately 4% for every 20 mm Hg increase of concurrent SBP (Table 2.4).   
There was little evidence that the relationship between concurrent SBP to change 
in SEVLT was moderated by concurrent hypertensive medication use (P=0.1).  Although 
separate analyses stratified by concurrent medication use did not indicate that concurrent 
SBP was statistically significantly related to change in SEVLT among either concurrent 
hypertension medication users or non-users, the direction and size of the relationship are  
noteworthy:  concurrent hypertension medication users might improve SEVLT scores 
over time while SEVLT performance among non-medicated individuals may be impaired 
over time, for the same amount of increase in concurrent SBP.  Furthermore, it appeared 
that non-medicated individuals with uncontrolled SBP (>=140 mmHg) tended to have a 
larger decline in SEVLT scores over time.      
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Second, the cross-sectional relationship (across all 7 visits) between time-
dependent SBP to cognitive function tests was examined to determine if it was dependent 
on hypertension medication use.   Results showed that only the relationship between 
adjusted SBP and mean 3MSE error was moderated by baseline hypertension medication 
use after adjusting for all covariates (Table 2.5).   In a separate analysis stratified by 
baseline hypertension medication use, time-dependent SBP was statistically significantly 
associated with higher mean error in 3MSE among baseline medication users.  Within 
this group of baseline medication users, those who had uncontrolled SBP (>=140 mm 
Hg) had 7% more mean error in 3MSE as compared to those who had controlled SBP 
(Table 2.5).   
Nonlinear relationship between SBP and cognitive function tests:  Nonlinear 
effects of SBP were examined by including squared SBP in the baseline and time-
dependent models.  However, there was no evidence of a statistically significant 
curvilinear relation to either cognitive function test. 
Diastolic Blood Pressure 
Baseline DBP and cognitive function tests:  Table 2.6 presents the relationship 
between baseline diastolic blood pressure and cognitive function tests. Baseline models 
indicated that unadjusted DBP at baseline was not associated with mean error in 3MSE 
and mean score in SEVLT (model I and III), and there was no evidence of a longitudinal 
relationship between adjusted DBP at baseline and mean error in 3MSE (Model II).  
However, DBP at baseline was statistically significantly associated with change in 
SEVLT performance over time after adjusting for all covariates (model IV):  for every 
SD (11 mmHg) increase of DBP at baseline, an annual increase in SEVLT score was 
approximately 0.04 points. 
Time-dependent DBP and cognitive function tests:  Adjusted time-dependent 
models demonstrated a longitudinal relationship between time-dependent DBP and 
change in 3MSE error and SEVLT score (model II and IV):  the annual decline of error in 
3MSE was approximately 1% and the annual increase of SEVLT score was 
approximately 0.06 points, for every SD (11 mm Hg) increase in concurrent DBP (Table 
2.7).  Figure 2.2 displays how time-dependent DBP influenced mean error in 3MSE at 
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each visit during the study period from baseline to the 6th year.  The study period was 
also extended beyond year 6 to illustrate the longitudinal impact of concurrent DBP on 
3MSE performance over a longer period of time.  At baseline, the mean error in 3MSE 
increased by 5% for every 11 mmHg increase of DBP.  With a change in rate (slope) of 
approximately -1%, the size of the increase in mean error in 3MSE at each follow-up visit 
attenuated over the study period.  After the 6th year, however, the mean error in 3MSE 
declined at each following visit for every 11 mmHg increase of DBP.  Similarly, Figure 
2.3 demonstrates how time-dependent DBP influenced SEVLT performance at each visit 
during the study period from baseline to the 6th year.   
Subgroup analyses were also performed to explore if the longitudinal relationship 
between concurrent DBP and performance in cognitive function tests was stronger among 
subjects with lower DBP.  The restricted analysis revealed that among those with low 
DBP (<=60 mmHg), the annual increases of SEVLT scores were more pronounced, with 
approximately 0.4 points per every 11 mmHg increase in concurrent DBP.   Although the 
longitudinal relation to 3MSE error was not statistically significant for those with DBP 
<=60 mmHg, the magnitude of the inverse relation appeared much larger in this group 
compare to those with higher DBP. 
Moderation of hypertension medication to the association between DBP and 
cognitive function: There was no interaction between hypertension medication use at 
baseline or over time with concurrent DBP on change (RX*DBP*time) or mean level 
(RX*DBP) in 3MSE or SEVLT.   
Nonlinear relationship between DBP and cognitive function tests:  The nonlinear 
relationship between DBP and cognitive performance were examined by including 
squared DBP in both baseline and time-dependent models.  There was no statistically 
significant complex relation to 3MSE performance.  There was a marginally significant 
nonlinear relationship between baseline and concurrent DBP to SEVLT performance in 
the unadjusted models.  However, this nonlinear relationship disappeared after 
adjustment for potential confounders.     
2.5 Discussion 
In this community-based longitudinal study of elderly Mexican Americans, we 
assessed the longitudinal and cross-sectional relationship between SBP and DBP and 
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cognitive function.  Longitudinal findings revealed that higher baseline SBP was 
associated with longitudinal decline in cognitive performance in both tests, and higher 
concurrent SBP was related to longitudinal decline in 3MSE performance among 
untreated individuals.  Untreated individuals with uncontrolled SBP were at the highest 
risk of cognitive decline over time.  These data indicated that SBP and DBP displayed a 
differential relationship with cognitive outcomes in late life.  The longitudinal findings 
revealed that higher concurrent DBP was associated with longitudinal improvement in 
cognitive performance in both tests, and higher baseline DBP was associated with 
longitudinal improvement in SEVLT scores.  This longitudinal improvement was more 
pronounced among individuals with low DBP.  In addition, cross-sectional findings 
demonstrated that higher concurrent SBP was associated with lower levels of cognitive 
performance in both tests, and treated individuals with uncontrolled SBP were more 
vulnerable to the deleterious effect of high SBP.  Additional controlling of baseline SBP 
and DBP in all time-dependent models did not change our findings.   
The results of previous population-based studies of blood pressure and cognitive 
function have been inconsistent, possibly due to use of different study designs, 
measurements of cognitive function, timing of blood pressure measurements, and length 
of follow-up.  Among five studies reporting an inverse association between blood 
pressure in late life and cognitive performance (19-23), the Cardiovascular Health Study, 
the only study with more than two follow-up visits, found a linear relation between SBP 
and decline in cognitive function over time.  These results are consistent with our finding 
of an inverse relationship between SBP in the elderly with change in cognitive function 
over time.  The observation that low DBP in late life could be a threat to cognitive 
function has been documented in two studies (11, 16), although both studies reported a 
curvilinear relationship between DBP and cognitive performance.  Our data suggest a 
linear relationship between DBP in late-life and change in cognitive function, and adds 
additional evidence to support of the unfavorable effect of DBP decline over time on 
cognition in elderly.  Tests for nonlinear relation of DBP to cognitive function in this 
study did not reveal a statistically significant curvilinear relation to either cognitive 
function test.   
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Epidemiological studies have demonstrated evidence of a protective role of 
antihypertensive therapy in preserving cognitive function among elderly:  Tzourio et al. 
reported that untreated hypertensive patients were at the highest risk for cognitive decline 
over 4 years (19).  Waldstein et al. and Guo el al. found that the deleterious effects of 
high SBP on cognitive decline were strongest among people who did not taking 
hypertensive medication (11, 13).   In addition, clinical trial data from HOPE (The Heart 
Outcomes Prevention Evaluation), PROGRESS (Perindopril Protection Against 
Recurrent Stroke Study), and Syst-Eur (Systolic Hypertension in Europe) trial (32-35) 
showed protective effect of antihypertensive treatment on cognitive decline and 
development of dementia among systolic hypertensive patients or patients with history of 
stroke and other vascular diseases.  Our results that untreated individuals, and in 
particular, those with uncontrolled systolic blood pressure, were at highest risk of 
cognitive decline are consistent with epidemiological studies and clinical trials. 
It is noteworthy that all associations found in this study were fairly small in 
magnitude.  This is consistent with results from four studies investigating the relationship 
between blood pressure in late life and cognitive function (11, 14, 16, 20). These four 
studies had at least two follow-up visits and applied either GEE or linear mixed model 
analyses.  Our observation of small effect may also be explained, in part, by the fact that 
the use of hypertension medications was prevalent in this population, which may 
attenuate the effect of high blood pressure on lower level of cognitive performance.        
Potential mechanisms of action by which high systolic blood pressure could lower 
cognitive performance include ischemic stroke (36-37); cerebrovascular damage such as 
white matter lesions and multiple small infarcts (38-39); vessel wall pathology such as 
atherosclerosis and arteriolosclerosis, insufficient cerebral blood flow (40-41); brain 
atrophy (42-43); and endothelia dysfunction and NO deficiency induced by oxidative 
stress and inflammatory responses (44-46).  The relevant mechanisms of action by which 
decline in diastolic blood pressure in elderly could negatively affect cognitive 
performance include cerebral hypo-perfusion, and associated neuron-pathology due to 
insufficient cerebral perfusion, ischemic hypoxia, and atherosclerosis (28, 42, 47-48).   
Studies suggest that low diastolic may be an indicator of increased large arterial stiffness 
and widespread atherosclerosis in elderly people (48-50).  It is possible that, over time, 
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the combination of high systolic blood pressure and low diastolic blood pressure may 
accelerate the process of cognitive impairment and lead to development of dementia and 
AD (11).      
Important strengths of this analysis include the advantage of a prospective 
longitudinal design with an average of 6-years follow-up, annual home inspection of 
medications, in addition to semi-annually phone interviews, annual measurement of 
blood pressure by trained personnel, and annual measurement of cognitive performance.  
This study is one of the few that examine blood pressure and cognitive measurements at 
more than 2 follow-up visits.  These factors greatly strengthen measurement reliability 
and allow for the study of individual change, rather than level of performance at a single 
point, in cognitive test performance.  Thus, these results may provide a more accurate 
assessment of cognition and its relationship with blood pressure.  Limitations of this 
study include the restriction of the assessment of cognitive function to two tests.  It is 
possible that a broader range of cognitive function testing may provide more definitive 
results.  In addition, there may exist potential residual confounding due to omitted 
covariates associated with both the exposure and outcome variables.  The inclusion of 
only Mexican American participants in the study may limit the generalization of the 
study results.   
Hypertension and cognitive impairment are significant public health problems. 
The prevalence of systolic hypertension and cognitive impairment increases substantially 
with age (1, 51-52).  In contrast, diastolic blood pressure rises up to age 50-59 and then 
starts to drop with age (51).  Our findings that higher SBP and lower DBP in elderly were 
associated with diminished cognitive function over time reinforce the need for and 
importance of identifying potential modifiable risk factors associated with decline in 
cognition in the elderly.  Future research in this area should include investigating the 
effect of both high and low blood pressure.  Our findings that untreated individuals with 
uncontrolled systolic blood pressure were at highest risk of cognitive impairments 
suggest that there is a need to better understand the protective effect of antihypertensive 
treatment, in particular, the specific class of agents that best preserve cognitive function 
in late life.  Randomized controlled trials will be needed to address these questions.   
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In addition, this is the first study to focus on the relation of blood pressure and 
cognitive decline in the elderly Mexican Americans, a young and rapidly growing but 
understudied ethnic population.  It is likely that aging in this population will lead to an 
increase of the prevalence of hypertension, cognitive impairment, and dementia in 
coming years.  Studies have shown that Mexican Americans had increased risk of stroke 
and better post-stroke survival as compared with non-Hispanic Whites (53-54).   Higher 
prevalence of stroke, diabetes and central obesity, lower socio-economic status, poorer 
access to health cares among Mexican Americans as compared with non-Hispanic Whites 
present a great challenge to manage these risk factors associated with cognitive 
impairment (24, 54-55).   The data from this study provided with a unique opportunity to 
identify and better understand the potential modifiable risk factors associated with 
cognitive impairment among elderly Mexican Americans.     
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2.6 Tables and Figures 
Table 2.1 Summary of Baseline Characteristics (a) 
Gender  [N(%)]
         Male 699 (42)
         Female 975 (58)
Age (years) 
         Mean (SD) 70 (6.80)
         Median (Minimum, Maximum) 69 (59, 98)
Education (Years)
         Mean (SD) 7.3 (5.33)
         Median (Minimum, Maximum) 7 (0, 32)
Smoking Status [N(%)]
        Never 762 (46)
        Former Smoker 709 (42)
        Current Smoker 191 (11)
Missing 12
Waist circumference (inches)
Mean (SD) 38.19 (5.24)
        Median (Minimum, Maximum) 38 (16, 58)
History of Stroke [N(%)]
         Yes 131 (8)
         No 1533 (92)
 Missing 10
Diabetes [N(%)](b)
        Yes 531 (32)
        No 1133 (68)
Missing 10
Heart Disease [N(%)] (c)
Yes 234 (14)
        No 1440 (86)
Systolic Blood Pressure 
Mean (SD) 138 .38(19.30)
Median (Minimum, Maximum) 137 (76, 230)
Diastolic Blood Pressure 
Mean (SD) 76.01 (10.58)
Median (Minimum, Maximum) 76 (34, 119)
        Any hypertension drug use [N(%)] 
         Yes 696 (42)
         No 975 (58)
         Missing 3
Hypertension [N(%)](d)
        Yes 1019 (61)
        No 517 (31)
Missing 138 (8)
      3MSE Score
Mean (SD) 85.88 (11.56)
        Median (Minimum, Maximum) 89 (11, 100)
      SEVLT Score
Mean (SD) 8.6 (2.90)
        Median (Minimum, Maximum) 9 (0, 15)
a. Include only the subjects who were dementia/CIND free at baseline  
b.  Participants were considered to have diabetes if they met any of the following 3 criteria:  Fasting 
plasma glucose (FPG) level >=126 mg/dL (7.0 mmol/L); or use of an antidiabetic medication; or self 
report of a physician’s diagnosis of diabetes.
c.  Participants were considered to have heart disease if they had the following 3 medical conditions: 
MI, angina pectoris, or congestive heart failure.   
d.  Hypertension was defined as systolic blood pressure >=140 or diastolic blood pressure >=90 or on 
hypertension medication.  
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Table 2.2 Relationship between Baseline (BL) Systolic Blood Pressure (SBP) and 
Cognitive Function Tests 
Model I Model II Model III Model IV
Parameters Unadjusted  Adjusted (c) Unadjusted  Adjusted (c) 
BL SBP
    (95% CI)
 0.006388****
 ( 0.004394, 0.008381)







    (95% CI)
0.000879****    
(0.000443, 0.001315) -0.00201* 
(-0.00366, -0.00035)
**** P value <0.0001; *** P value <0.001; ** P value <0.01; * P value <0.05
a.  Dependent variable was defined as natural log of error in measuring 3MSE (ln(101-3MSE)); 
     3MSE=Modified Mini-Mental State Examination
b.  SEVLT (Spanish English Verbal Learning Test ) is a delayed word list recall test
c.  Adjusted for baseline age, education, gender, diabetes, history of stroke, and smoking status 




Table 2.3 Relationship between Time-Dependent (TD) Systolic Blood Pressure 
(SBP) and Cognitive Function Tests 
Model I Model II Model III Model IV
Parameters Unadjusted  Adjusted (c) Unadjusted  Adjusted (c)
TD SBP 
    (95% CI)
0.000765            
(-0.00009, 0.001616)







    (95% CI)




**** P value <0.0001; *** P value <0.001; ** P value <0.01; * P value <0.05
a.  Dependent variable was defined as natural log of error in measuring 3MSE (ln(101-3MSE))
b.  SEVLT (Spanish English Verbal Learning Test ) is a delayed word list recall test
c.  Adjusted for baseline age, education, gender, diabetes, history of stroke, and smoking status 
d.  Marginally statistically significant: p value =0.05








Table 2.4 Longitudinal Relationship between Time-Dependent (TD) Systolic Blood 
Pressure (SBP) and 3MSE Performance (a)  
Parameters Adjusted (b)
Model 1 (c)
     Longitudinal relation of SBP by moderation of 
TD hypertension medication use
TD SBP* Time (95% CI) -0.00035 (-0.00083, 0.000132)
TD SBP*TD RX Use *Time  (95% CI) (d)  0.001351** (0.000575, 0.002127)
Model 2 
     Among uncontrolled SBP subjects (SBP>=140 
mm Hg) who did not take hypertension medication
TD SBP* Time (95% CI)  0.001861** (0.000517, 0.003204)
**** P value <0.0001; *** P value <0.001; ** P value <0.01; * P value <0.05
a.  Dependent variable was defined as natural log of error in measuring 3MSE (ln(101-3MSE))
b.  Adjusted for baseline age, education, gender, diabetes, history of stroke, and smoking status
c. Adding three way interaction of SBP*RX*Time to understand if longitudinal effect of time-dependent SBP on 
3MSE performance depended on hypertension medication use. 
d.  Hypertension medication user was reference group  
 
 
Table 2.5 Cross-Sectional Relationship between Systolic Blood Pressure (SBP) and 
3MSE Performance (a) 
Parameters Adjusted (b)
Model 1 (c)
     Cross-sectional relation of SBP by moderation of 
hypertension medication use at baseline (BL) 
TD SBP (95% CI) -0.00016 (-0.00130, 0.000974)
TD SBP* BL RX Use  (95% CI) (d) 0.001935* (0.000340, 0.003530)
Model 2 (c)
     Among BL hypertension medication users
TD SBP (95% CI) (e) 0.06482** (0.02062, 0.1090)
**** P value <0.0001; *** P value <0.001; ** P value <0.01; * P value <0.05
a.  Dependent variable was defined as natural log of error in measuring 3MSE (ln(101-3MSE))
b.  Adjusted for baseline age, education, gender, diabetes, history of stroke, and smoking status
c.  Longitudinal effect of SBP (SBP*Time) was not statistically significant and not included in the model
d.  Non-hypertension medication user was reference group
e.  SBP was categorized as two groups: SBP >=140 and SBP <140 mm Hg;  SBP<140 was reference group  
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Table 2.6 Relationship between Baseline (BL) Diastolic Blood Pressure (DBP) and 
Cognitive Function Tests 
Model I Model II Model III Model IV
Parameters Unadjusted  Adjusted (c) Unadjusted  Adjusted (c)
BL DBP














**** P value <0.0001; *** P value <0.001; ** P value <0.01; * P value <0.05
a.  Dependent variable was defined as natural log of error in measuring 3MSE (ln(101-3MSE))
b.  SEVLT (Spanish English Verbal Learning Test ) is a delayed word list recall test
c.  Adjusted for baseline age, education, gender, diabetes, history of stroke, and smoking status




Table 2.7 Relationship between Time-Dependent (TD) Diastolic Blood Pressure 
(DBP) and Cognitive Function Tests 
Model I Model II Model III Model IV
Parameters Unadjusted  Adjusted (c) Unadjusted  Adjusted (c)
TD DBP














**** P value <0.0001; *** P value <0.001; ** P value <0.01; * P value <0.05
a.  Dependent variable was defined as natural log of error in measuring 3MSE (ln(101-3MSE))
b.  SEVLT (Spanish English Verbal Learning Test ) is a delayed word list recall test
c.  Adjusted for baseline age, education, gender, diabetes, history of stroke, and smoking status
d.  Marginally statistically significant: p value =0.05











Figure 2.1 Relationship between Baseline SBP and 3MSE Performance (per 20 mm 































(after 20 mm Hg increase of SBP)
3MSE 
(reference: no SBP incraese)
*This new 3ME score represents 14% increase in the mean error in 3MSE
 due to increase of SBP at baseline 
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Figure 2.2 Longitudinal and Cross-Sectional Relationship between Concurrent DBP 




































*Longitudinal relation: change rate was approxiamtely -1%
 Cross-sectional relation: mean error change in 3MSE at each visit
Study Year
 
Figure 2.3 Longitudinal and Cross Sectional Relationship between Concurrent DBP 

































*Longitudinal relation: change rate was approxiamtely 0.06 points
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PULSE PRESSURE AND CHANGE IN COGNITIVE FUNCTION IN ELDERLY 
MEXICIAN AMERICANS: A POPULATION-BASED COHORT STUDY 
3.1 Abstract 
OBJECTIVE:  Few population-based studies have examined the relationship between 
pulse pressure in late life and decline in cognitive function.  The objective of this study 
was to test the association between baseline and time-dependent pulse pressure and 
decline in cognitive function over 6 years of follow-up among older Mexican Americans 
living in the Sacramento, California area. 
RESEARCH DESIGN AND METHODS: The Sacramento Area Latino Study of Aging 
(SALSA) was a prospective longitudinal cohort study with an average length of follow-
up of 6.11 years.  Eligible community-dwelling, non-institutionalized Latinos aged 60 
years and older in 1998-99 (n=1768) were enrolled in the study, and followed from 
1998/99 through 2007.  A total of 1674 individuals who had no prevalent dementia and 
were not “cognitively impaired not demented” (CIND) at baseline and had available data 
for at least baseline measurements were included in the study.  Cognitive assessments 
using “Modified Mini-Mental State Examination (3MSE)” and “Spanish English Verbal 
Learning Test (SEVLT)”, and measurements of systolic blood pressure and diastolic 
blood pressure were performed at baseline and at each of the 6 follow-up visits.  Pulse 
pressure was calculated as the difference of systolic and diastolic blood pressure.  Linear 
regression models with mixed (fixed and random) effects were used to assess the 
association between pulse pressure and cognitive function.   
RESULTS:  Longitudinal findings indicated that (i) higher baseline pulse pressure was 
associated with longitudinal decline in both cognitive performance tests: an annual 
increase of error in 3MSE was 2% (1.4%, 3.1%) and an annual decline of SEVLT score 
was -0.07 (-0.1, -0.03) points, for every 18 mm Hg increase in PP at baseline; (ii) higher 
concurrent pulse pressure was associated with longitudinal decline in 3MSE 
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performance:  an annual increase of error in 3MSE was 1% (0.3%, 1.8%) for every 18 
mm Hg increase in PP; (iii) higher concurrent pulse pressure was related to longitudinal 
decline in both tests among untreated participants: an annual increase of error in 3MSE 
was 2% (0.8%, 3.5%), an annual decline in SEVLT score was -0.06 (-0.11, -0.01)  points, 
for every 18 mm Hg increase in pulse pressure;  (iv) the annual decline was more 
pronounced among untreated individuals with higher pulse pressure (>=70 mm Hg):  an 
annual increase of error in 3MSE was 4.5% (1%, 8.2%) for every 18 mm Hg increase in 
pulse pressure.  In addition, cross-sectional findings (across all visits) indicated a U 
shaped relationship between concurrent pulse pressure and cognitive performance: both 
low and high pulse pressure were associated with a higher mean error in 3MSE and lower 
mean score in SEVLT.  All associations found in this study were fairly small in 
magnitude.     
CONCLUSION: Results of 6 years of follow-up data from the SALSA study 
demonstrated that higher pulse pressure was associated with longitudinal decline in 
cognitive function after adjusting for potential confounding variables; and untreated 
individuals with high pulse pressure were at highest risk of cognitive impairments.  The 
results also revealed a U shaped relationship between concurrent pulse pressure with 
mean errors in 3MSE and mean scores in SEVLT:  both low and high pulse pressure were 
associated with poor cognitive performance.  These results suggested an important role of 
optimal pulse pressure to preserve cognitive function in the elderly. 
3.2 Introduction 
Increasing evidence suggests that hypertension may contribute to diminished 
cognitive function (1-14).  The effects of hypertension on cognitive impairment, 
however, may be modified by age as systolic blood pressure increases with age for men 
and women, while diastolic blood pressure increases up to age 50-59 and then begins to 
decline with age for both genders (15).  The difference between systolic blood pressure 
and diastolic blood pressure (defined as pulse pressure), thus, increases steeply among 
older people as they continue to age.   
High pulse pressure in the elderly is a marker of increased artery stiffness and 
widespread atherosclerosis (16-19) that has been linked with a risk of cognitive 
impairment and dementia.  It is therefore possible that higher pulse pressure is associated 
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with worse cognitive performance in elderly over time.  However, few population-based 
longitudinal studies have examined the effects of the pulse pressure on cognitive decline 
in the elderly population (20-21).  The Baltimore Longitudinal Study reported that higher 
pulse pressure in late life was associated with accelerated decline in cognitive function, in 
particular, learning, memory, and concentration, over time (20).  In addition, two other 
epidemiological studies investigated the relationship between pulse pressure and risk of 
dementia and Alzheimer’s disease.  Kungsholmen project found a U-shape relation 
between level of pulse pressure and risk of Alzheimer’s disease and dementia in those 
aged 75 and older (21).   The East Boston Study, a community-based cohort study, 
however, found marginal evidence of the association between high pulse pressure and an 
increased risk of Alzheimer’s disease in adults aged 65 and older (22).  
The objective of this study was to assess the association between baseline and 
time-dependent pulse pressure and decline in cognitive function over 6 years of follow-up 
among older Mexican Americans living in the Sacramento, California area. 
3.3 Methods 
Study population:  A detailed description of sampling and recruitment in the 
Sacramento Area Latino Study of Aging (SALSA) has been described elsewhere (23).  
SALSA was a prospective longitudinal cohort study designed to examine whether risk 
factors (diabetes, hypertension, smoking and obesity) increase the risk of dementia, 
memory loss, functional impairment, and decline in cognitive and physical functioning 
(23).  At baseline, a total of 1789 eligible community-dwelling, non-institutionalized 
Latinos aged 60 years and older, who lived in the Sacramento area and San Joaquin 
Valley in California, were enrolled in the study and followed from 1998/99 through 2007.  
The average length of follow-up was 6.11 years and the maximum length was 9 years.  
Among 1789 SALSA participants, 115 had dementia or “cognitive impairment not 
demented” (CIND) at baseline and were excluded from this analysis.  Thus, the analytical 
sample included 1674 subjects who had no prevalent dementia or CIND at baseline and 
had available data for at least baseline measurements.   
Outcome measurement – 3MSE and SEVLT:   The Modified Mini-Mental State 
Examination (3MSE) and the Spanish English Verbal Learning Test (SEVLT) were 
performed for each participant at each home visit and at each of the 6 annual follow-up 
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visits.  The 3MSE is a 100 point cognitive exam that measures global cognitive function 
by testing orientation to time and space, registration, attention and concentration, recall 
and delayed recall, verbal fluency and abstract verbal reasoning, visual construction, etc. 
(24).  Higher test scores indicate better global cognitive performance.  It has been 
validated in Spanish and widely used as a screening instrument for Alzheimer's disease or 
dementia (1, 25-30).  The SEVLT is a delayed word list recall test with five 15-word 
trials (31) interrupted by a distracter list.  It measures short term verbal recall. The test 
consists of five semantic categories with examples of vegetables, drinks, kitchen utensils, 
reading materials, and fruit (31).  The test scores range from 0 to 15 with higher scores 
indicating better performance.   
Exposure measurement – pulse pressure:  Pulse pressure was calculated as the 
difference between systolic and diastolic blood pressure at baseline and at each of the 6 
follow-up visits.  At baseline and at each of 6 annual visits, systolic and diastolic blood 
pressures were measured by trained staff using an automatic digital blood pressure 
monitor (OMRON MODEL: HEM-747 IC) calibrated biannually.  Two readings of 
sitting measurements after a 5-minute rest were taken and the average of the 
measurements was analyzed.   
Measurement of Covariates:  A total of eight baseline covariates were included in 
the initial analyses.  Age, measured in years, was calculated from dates of birth and 
baseline visit; sex and education, measured in years, were collected at the baseline visit; 
waist circumference, measured at the level of maximum indentation over the abdomen, 
when the participant bended to the side, was taken in centimeters at baseline and 
converted to inches; smoking status was assessed by asking each participant to select one 
of three responses that best described their smoking status at the baseline visit:  never 
smoker, former smoker, or current smoker;  history of stroke was determined by self 
report of a physician’s diagnosis at the baseline visit;  history of heart disease was 
determined by self report of a physician’s diagnosis at baseline by answering “yes” to the 
questions about MI, Angina pectoris, or congestive heart failure;  diabetes was 
ascertained if a participant met the following 3 criteria at baseline:  fasting plasma 
glucose (FPG) level ≥126 mg/dL (7.0 mmol/L) (fasting was defined as no caloric intake 
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for at least 8 hours), or use of an anti-diabetic medication, or self-report of a doctor’s 
diagnosis of diabetes. 
In addition, antihypertensive medication use at baseline and over time was 
included in the analyses as a potential modifier.   Antihypertensive drugs included all 
medications potentially used for lowering blood pressure.  The use of antihypertensive 
drugs was ascertained at each participant’s home at baseline and at each follow up visit 
by direct inspection of all medications.  Trained personnel entered the medication 
information such as medication code, dose, number of prescribed pills, and average 
number of pills taken onto the collection form. This information was then updated by 
telephone every 6-8 months between home visits. Medication codes were assigned using 
the Centers for Disease Control (CDC) Ambulatory Care Drug Database System (32).  
Statistical analyses: The association between pulse pressure and cognitive 
function was assessed by linear regression models with mixed (fixed and random) effects.  
These models allowed for the examination of both the cross-sectional (across all visits or 
at a given visit) and longitudinal (change over time) relationships between pulse pressure 
and cognitive function.  The cross-sectional relationship was indicated by pulse pressure 
main effects or interactions between pulse pressure and each of the covariates, while the 
longitudinal relationship was represented by interactions between pulse pressure and time 
interval (or three-way interaction of pulse pressure, hypertensive medication use, and 
time interval).  The predictors of interest such as pulse pressure were entered as fixed 
effects into the models.  Random effects were modeled by taking into account the 
variability in initial level of 3MSE or SEVLT performance and rates of change between 
subjects.  The initial graphical analysis and a univariate test indicated that 3MSE data 
was skewed since most participants had high scores in their 3MSE test at baseline.  
Therefore, a natural log transformation of error in 3MSE (101-3MSE) was used as a 
dependent variable in all models to normalize the data.  A preliminary graphic analysis 
and a univariate test indicated that SEVLT data had a normal distribution and was 
directly used as the dependent variable in all models.      
Two sets of mixed models were applied to examine the association between pulse 
pressure and error in 3MSE, or SEVLT score:  the first set were baseline models testing 
the association between baseline pulse pressure and error in 3MSE or SEVLT score; and 
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the second set were time dependent models assessing the association between time-
dependent pulse pressure and error in 3MSE, or SEVLT score.  For each set of models, 
both unadjusted and adjusted effects of pulse pressure were examined.   Prior knowledge 
of biological plausibility as well as the change-in-estimate criterion was applied to 
determine covariates to be included in the final models.  Six baseline covariates including 
age (years), gender, education (years), diabetes (yes/no), history of stroke (yeas/no), and 
smoking status (current/former/never smoker) were used for adjustment in the final 
models.   
The moderation effects of hypertension medication used at baseline or over time 
were tested.   Stratified analyses were performed if a statistical interaction was suggested.  
Nonlinear relationship between pulse pressure and cognitive function was tested by 
including squared pulse pressure terms in the models.  In addition, based on tertile of 
pulse pressure, a categorical analysis was performed using concurrent pulse pressure as a 
categorical variable (<54 mm Hg, 54-69 mm Hg, and >=70 mmHg) to examine if there is 
nonlinear relationship between pulse pressure and cognitive function performance.   
All models were fit using SAS PROC MIXED.  Only statistically significant 
interaction terms (p<0.05) were included in the final models. 
3.4 Results 
Demographic characteristics:   The characteristics of individuals at baseline are 
presented in Table 3.1.  More than half of the participants were female (58%), mean age 
was 70 years, and mean education was 7.3 years.  Majority of individuals were not 
current smokers (88%).  Baseline prevalence of comorbidities included diabetes (32%), 
stroke (8%), and heart disease (14%).  On average, systolic and diastolic blood pressure 
at baseline was 138 mm Hg and 76 mm Hg respectively.  Mean pulse pressure was 62 
mm Hg.  Hypertension at baseline was prevalent (61%).  Although less than half of 
individuals used anithypertensive medication at baseline (42%), usage increased over 
time and reached 52% at the 3rd visit and 70% at the 6th visit.  Most of individuals scored 
well in the 3MSE test at baseline with a median score of 89 out of 100.  Average score of 
SEVLT at baseline was 8.6 out of 15.  
Baseline pulse pressure and cognitive function tests:  Table 3.2 presents the 
relationship between baseline pulse pressure and cognitive function tests.  Unadjusted 
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baseline pulse pressure was statistically significantly associated with a higher mean error 
in 3MSE and lower mean score in SEVLT:  for every one standard deviation (SD=18 mm 
Hg) increase in baseline pulse pressure there was a 17% increase in mean error in 3MSE 
and 0.5 points drop in mean score in SEVLT (model I and III).  There was a longitudinal 
relationship between baseline pulse pressure and 3MSE and SEVLT performance after 
adjusting for all covariates (model II and IV): an annual increase of error in 3MSE was 
approximately 2% and annual decline of SEVLT score was approximately 0.07 points, 
for every 18 mm Hg increase in pulse pressure at baseline.    
The baseline models including higher-order terms for pulse pressure did not 
demonstrate a statistically significant quadratic relationship with both cognitive function 
tests.  
Time-dependent pulse pressure and cognitive function tests:   Table 3.3 presents 
the relationship between time dependent pulse pressure and cognitive function tests.  
First, adjusted time-dependent model revealed a cross-sectional relationship between 
nonlinear pulse pressure and 3MSE performance (model II).  Both low and high pulse 
pressure appeared to be linked to a higher level of predicted errors in 3MSE.  
Furthermore, Figure 3.1 shows that pulse pressure influenced 3MSE performance 
differently for people with low and high pulse pressure at baseline:  given a 18 mm Hg 
increase in pulse pressure at baseline, subjects with initial pulse pressure of 30 mm Hg 
had a 8% decline in mean error in 3MSE, whereas subjects with initial pulse pressure of 
100 mm Hg had a 4% increase in mean error in 3MSE.    
Second, this nonlinear time-dependent model also revealed a longitudinal 
relationship between concurrent pulse pressure and change in error in 3MSE: the annual 
increase of error in 3MSE was approximately 1% for every 18 mm Hg increase in pulse 
pressure.  It should be noted that, while the longitudinal relationship between concurrent 
pulse pressure and 3MSE performance was linear, the size and direction of the influence 
of concurrent pulse pressure to 3MSE performance at each visit differed by the initial 
pulse pressure level of each subject (Figure 3.2), for the same amount of increase in pulse 
pressure.  For example, an 18 mm Hg increase in pulse pressure was beneficial to the 
3MSE performance of individuals with an initial level of pulse pressure equal to 30 mm 
Hg, as mean error in 3MSE declined at each visit; whereas the same amount of increase 
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in pulse pressure adversely affected the performance of those with an initial level of pulse 
pressure equal to 80 mm Hg, as mean error in 3MSE increased at each visit.  However, 
over time, the size of change in 3MSE performance favorable to people with low pulse 
pressure attenuated while the size of the change unfavorable to people with high pulse 
pressure increased.      
Third, in the unadjusted time-dependent model, the concurrent pulse pressure was 
statistically significantly associated with SEVLT score:  for an 18 mm Hg increase in 
concurrent pulse pressure, mean score in SEVLT dropped by 0.1 points (model III).  In 
the adjusted model, neither cross-sectional nor longitudinal relationship between pulse 
pressure and the mean score or change in SEVLT was observed (model IV).  Nonlinear 
effects of pulse pressure were tested by including squared pulse pressure in the time-
dependent models, but no evidence of a statistically significant complex relationship to 
SEVLT performance was observed. 
Moderation effect of antihypertensive medication on  the association of pulse 
pressure and cognitive function tests:   Antihypertensive medication use at baseline and 
over time was examined to determine if it moderated the cross-sectional and longitudinal 
relationship between concurrent pulse pressure and cognitive function tests.   The results 
indicated that the influence of concurrent pulse pressure on changes in 3MSE 
performance over time was dependent on concurrent hypertensive medication use.  The 
separate analysis by antihypertensive medication use indicated that an annual increase of 
error in 3MSE per 18 mm Hg increase concurrent pulse pressure was approximately 2% 
among the non-users of hypertension medication.  Further restricting the analysis to those 
non-users with high pulse pressure (>=70 mm Hg) demonstrated that an 18 mm Hg 
increase in concurrent pulse pressure corresponded to an annual increase of error in 
3MSE of approximately 4.5% (Table 3.4).   
Although the influence of concurrent pulse pressure on longitudinal SEVLT 
performance in the entire sample was not dependent on either concurrent or baseline 
hypertension medication use, the restricted analyses demonstrated that there was a 
longitudinal relationship between concurrent pulse pressure and SEVLT performance 
among non-users of hypertension medication at baseline or over time (Table 3.5):  for 
every 18 mm Hg increase in concurrent pulse pressure, the annual decline in SEVLT 
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score was approximately 0.06 points and 0.05 points respectively, among those not taking 
antihypertensive medication over time and at baseline.     
Categorical analysis of the association between pulse pressure and cognitive 
function:   Using the median tertile (54<=pulse pressure<70) as the referent group, we 
found a U-shaped relationship between concurrent pulse pressure and mean error in 
3MSE and mean score in SEVLT (Table 3.6):  an individual with a pulse pressure <54 
mm Hg had 9% higher mean error in 3MSE and 0.2 points lower mean score in SEVLT 
than an individual with a pulse pressure between 54 and 69 mm Hg; an individual with a 
pulse pressure >=70 mm Hg had a 6% higher mean error in 3MSE and 0.2 points lower 
mean score in SEVLT than an individual with a pulse pressure between 54 and 69 mm 
Hg.    The longitudinal association between time-dependent pulse pressure and change in 
SEVLT score was statistically significant when comparing untreated individuals with 
higher pulse pressure (>=70 mm Hg) to untreated individual with a pulse pressure 
between 54 and 69 mm Hg:  the annual decline in SEVLT score was approximately 0.1 
point.    
3.5 Discussion 
In this community-based longitudinal study of elderly Mexican Americans, the 
longitudinal and cross-sectional relationship between pulse pressure and cognitive 
function was assessed.  The longitudinal findings revealed that higher baseline pulse 
pressure was associated with longitudinal decline in cognitive performance in both tests, 
higher concurrent pulse pressure was related to longitudinal decline in 3MSE 
performance, and higher concurrent pulse pressure was related to longitudinal decline in 
both cognitive performance tests among untreated participants.  The annual decline most 
adversely affected the cognitive performance of untreated individuals with high pulse 
pressure (>=70 mm Hg).   In addition, cross-sectional findings suggested a U shaped 
relationship between concurrent pulse pressure and mean errors in 3MSE and mean 
scores in SEVLT:  both low and high pulse pressure was associated with poor cognitive 
performance in both tests.  Statistical significance of the observed associations persisted 
when additional adjustment for SBP and DBP was included in all adjusted models.  
Controlling of baseline pulse pressure in the time-dependent models did not change the 
study results.      
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The association between high pulse pressure and longitudinal decline in cognitive 
function is consistent with that reported by the Baltimore Longitudinal Study (16), the 
only study which has specifically examined the association of pulse pressure in late life 
and cognitive decline over time.  Although our study population was older, considerably 
less educated and of Mexican decent (versus a predominantly white population in the 
Baltimore study), our results presented a similar pattern between pulse pressure and 
change in cognitive function over time.  However, there were two differences noted.  
First, while we found a statistically significant relation between high pulse pressure and 
cognitive decline over time using the 3MSE in our study, this was not the case in the 
Baltimore Longitudinal Study which used the MMSE (Mini-Mental State Examination).  
This may suggest that 3MSE, a modified MMSE, with broader variety of cognitive 
function and wider range of difficulty levels may have an enhanced ability to detect 
subtle changes in cognitive function associated with vascular risk, such as high pulse 
pressure (20, 24).  Second, a U-shaped relationship between concurrent pulse pressure 
and mean errors in 3MSE and mean scores in SEVLT was observed in our study, whereas 
no such relationship was evident in the Baltimore Longitudinal Study (20).  This may be 
explained in part by the difference in populations studied.  Our participants were older 
than those in the Baltimore Longitudinal Study (mean=70 vs. mean=57).  It is possible 
that lower pulse pressure linked to inadequate cerebral perfusion may be a bigger threat 
to older people.  The Kungsholmen project, a longitudinal study of elderly persons aged 
75 and older, found a U-shape relationship between the level of pulse pressure and risk of 
AD and all dementias (21), which is consistent with our findings.   
Among longitudinal studies investigating the relationship between pulse pressure 
and cognitive impairment, none have examined the role of antihypertensive therapy in 
preserving cognitive function among elderly. Our study results may be the first to 
demonstrate that untreated individuals, in particular, those with high pulse pressure (>=70 
mmHg), may be at highest risk of cognitive impairment.    
It is noteworthy that all associations found in this study were fairly small in 
magnitude.  This is consistent with the findings observed in the Baltimore Longitudinal 
Study, which had more than two follow-up visits and used linear mixed model analyses.  
Our modest results may be explained, in part, by the fact that the use of hypertension 
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medications was prevalent in our population, which may have attenuated the relationship 
between high pulse pressure and poor cognitive performance.         
High pulse pressure is positively associated with arterial stiffness and 
atherosclerosis (16-19, 33). Thus, it has been linked to an increased risk of cardiovascular 
diseases including stroke (34-38), which are also risk factors for cognitive decline and 
dementia (39-42). Studies have also shown that oxidative stress and inflammatory 
responses induced by arterial stiffness are involved with the mechanisms of vascular 
disorders and AD (43-44).  In addition, clinically silent cerebrovascular lesions, cerebral 
microcirculation damage, cerebral hypoperfusion, and other vessel pathology resulting 
from high pulse pressure appear to predispose individuals to the development of 
cognitive impairment and subsequent dementia (20-21, 44-45).  Low pulse pressure most 
likely contributes to the diminished cognitive function and dementia through cerebral 
hypofusion (21).  Both low and high pulse pressure may be precursors to chronic cerebral 
oxygen deprivation that is linked to cognitive decline and dementia in very elderly 
populations (4).  
Strengths of this study include the prospective collection of data over a 6-year 
period, annual home inspection of medications in addition to semi-annually phone 
interviews, annual measurement of blood pressure by trained personnel, annual 
measurement of cognitive performance, and wider age range from 59-98 years to better 
capture the change of pulse pressure in the elderly.  Our study measured pulse pressure 
and cognitive measurements at 6 follow-up visits.  This method of data collection 
strengthens measurement reliability and permits the examination of individual change in 
cognitive performance over time.  Therefore, it is likely to provide a more accurate 
measure of cognition and its relationship to pulse pressure.  Limitations of this study 
include the restriction of the assessment of cognitive function to two tests.  It is possible 
that a broader range of cognitive function testing may provide more definitive results.  In 
addition, there may exist potential residual confounding due to omitted covariates 
associated with both the exposure and outcome variables.  The inclusion of only Mexican 
American participants in the study may limit the generalization of the study results.   
Our finding that higher pulse pressure, a marker of arterial stiffness, is associated 
with the diminished cognitive function over time underscores the importance of 
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identifying the potentially modifiable risk factors for cognitive decline in the elderly and 
emphasizes the need to expand research in this area.  The additional finding that 
untreated individuals with higher pulse pressure were at highest risk of cognitive 
impairment suggests the need to further understand the protective effect of the 
antihypertensive treatment, and specific classes of agents in treating the risk factors 
associated with high pulse pressure in late life.  Future studies to examine the benefit of 
early intervention with appropriate pharmacological treatment, life-style changes, and 
diet to maintain an optimal cognitive level in the elderly may play an important role in 
reducing and/or delaying the onset of cognitive impairment and dementia. 
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3.6 Tables and Figures 
Table 3.1 Summary of Baseline Characteristics (a) 
 
Gender  [N(%)]
         Male 699 (42)
         Female 975 (58)
Age (years) 
         Mean (SD) 70 (6.80)
         Median (Minimum, Maximum) 69 (59, 98)
Education (Years)
         Mean (SD) 7.3 (5.33)
         Median (Minimum, Maximum) 7 (0, 32)
Smoking Status [N(%)]
        Never 762 (46)
        Former Smoker 709 (42)
        Current Smoker 191 (11)
Missing 12
Waist circumference (inches)
Mean (SD) 38.19 (5.24)
        Median (Minimum, Maximum) 38 (16, 58)
History of Stroke [N(%)]
         Yes 131 (8)
         No 1533 (92)
 Missing 10
Diabetes [N(%)](b)
        Yes 531 (32)
        No 1133 (68)
Missing 10
Heart Disease [N(%)] (c)
Yes 234 (14)
        No 1440 (86)
Systolic Blood Pressure 
Mean (SD) 138 .38(19.30)
Median (Minimum, Maximum) 137 (76, 230)
Diastolic Blood Pressure 
Mean (SD) 76.01 (10.58)
Median (Minimum, Maximum) 76 (34, 119)
Pulse Pressure 
Mean (SD) 62.36 (17.55)
Median (Minimum, Maximum) 60 (20, 151)
        Any hypertension drug use [N(%)] 
         Yes 696 (42)
         No 975 (58)
         Missing 3
Hypertension [N(%)](d)
        Yes 1019 (61)
        No 517 (31)
Missing 138 (8)
      3MSE Score
Mean (SD) 85.88 (11.56)
        Median (Minimum, Maximum) 89 (11, 100)
      SEVLT Score
Mean (SD) 8.6 (2.90)
        Median (Minimum, Maximum) 9 (0, 15)
a. Include only the subjects who were dementia/CIND free at baseline  
b.  Participants were considered to have diabetes if they met any of the following 3 criteria:  Fasting plasma glucose 
(FPG) level >=126 mg/dL (7.0 mmol/L); or use of an antidiabetic medication; or self report of a physician’s 
diagnosis of diabetes.
c.  Participants were considered to have heart disease if they had the following 3 medical conditions: MI, angina 
pectoris, or congestive heart failure.   
d.  Hypertension was defined as systolic blood pressure >=140 or diastolic blood pressure >=90 or on hypertension 
medication.  
67 
Table 3.2 Relationship between Baseline (BL) Pulse Pressure (PP) and Cognitive 
Function Tests 
Model I Model II Model III Model IV
Parameters Unadjusted  Adjusted (c) Unadjusted  Adjusted (c)
BL PP















**** P value <0.0001; *** P value <0.001; ** P value <0.01; * P value <0.05
a.  Dependent variable was defined as natural log of error in measuring 3MSE (ln(101-3MSE))
b.  SEVLT (Spanish English Verbal Learning Test ) is a delayed word list recall test
c.  Adjusted for baseline age, education, gender, diabetes, history of stroke, and smoking status 




Table 3.3 Relationship between Time-Dependent (TD) Pulse Pressure (PP) and 
Cognitive Function Tests 
Model I Model II Model III Model IV
Parameters Unadjusted  Adjusted (c) Unadjusted  Adjusted (c)
TD PP 
    (95% CI)














TD PP*TD PP 
    (95% CI) (d)
0.000046** 
(0.000015, 0.000076)
**** P value <0.0001; *** P value <0.001; ** P value <0.01; * P value <0.05
a.  Dependent variable was defined as natural log of error in measuring 3MSE (ln(101-3MSE))
b.  SEVLT (Spanish English Verbal Learning Test ) is a delayed word list recall test
c.  Adjusted for baseline age, education, gender, diabetes, history of stroke, and smoking status 
d.  TD PP*TD PP*Time was not statistically significant and not included in the final model 
e.  P vlaue =0.09
3MSE (a) SEVLT (b)
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Table 3.4 Longitudinal Relationship between Time-Dependent (TD) Pulse Pressure 




     Longitudinal relation of linear PP by moderation 
of TD hypertension medication use
PP* Time (95% CI) 0.000123 (-0.00041, 0.000650)
PP* RX Use *Time  (95% CI) (d) 0.001244** (0.000361, 0.002127)
Model 2
     Among high PP subjects (PP >=70 mm Hg) who 
did not take hypertension medication
PP* Time (95% CI) 0.002470** (0.000571  0.004369)
**** P value <0.0001; *** P value <0.001; ** P value <0.01; * P value <0.05
a.  Dependent variable was defined as natural log of error in measuring 3MSE (ln(101-3MSE))
b.  Adjusted for baseline age, education, gender, diabetes, history of stroke, and smoking status
c. Adding three way interactions of PP*RX*Time to understand if longitudinal relation of linear PP to 3MSE 
performance depended on time-dependent hypertensive medication use. 
d. Hypertension medication user was reference group  
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Table 3.5 Longitudinal Relationship between Time-Dependent (TD) Pulse Pressure 
(PP) and SEVLT (a) 
Parameters Adjusted (b)
Model 1 (c)
     Longitudinal relation of PP by moderation of TD 
hypertension medication use
PP* Time (95% CI) -0.00308* (-0.00579, -0.00036)
PP* RX Use *Time  (95% CI) (d) 0.002793 (-0.00058, 0.006164)
Model 2
     Among non-hypertension medication users
PP* Time (95% CI)   -0.00323* (-0.00599, -0.00048)
Model 3 (c)
     Longitudinal relation of PP by moderation of BL 
hypertension medication use
PP* Time (95% CI) -0.00284* (-0.00509, -0.00059)
PP* RX Use *Time  (95% CI) (e) 0.002942 (-0.00027, 0.006159)
Model 4
     Among non-hypertension medication users
PP* Time (95% CI) -0.00263* (-0.00491, -0.00035)
**** P value <0.0001; *** P value <0.001; ** P value <0.01; * P value <0.05
a.   SEVLT (Spanish English Verbal Learning Test ) is a delayed word list recall test
b.  Adjusted for baseline age, education, gender, diabetes, history of stroke, and smoking status
c. Adding three way interactions of PP*RX*Time to understand if longitudinal relation of concurrent PP on SEVLT 
performance depended on time-dependent (TD) or baselien (BL) hypertensive medication use. 
d. Non-hypertension medication user was reference group: P value=0.1 
e. Non-hypertension medication user was reference group: P value=0.07  
 
Table 3.6 U – Shaped Relationship between Time-Dependent (TD) Pulse Pressure 
(PP) and Cognitive Function – Categorical Analysis (a) 
Parameters Adjusted Model I (b) Adjusted Model II (b)
3MSE SEVLT
   1:PP< 54  (95% CI)       0.08711**** ( 0.05077, 0.1235) -0.1618* (-0.2961, -0.02748)
   2:PP>=70 (95% CI) 0.06089*** (0.02497, 0.09681) -0.1590* (-0.2923, -0.02565)
   3:54<=PP<70 (95% CI) Reference Reference 
**** P value <0.0001; *** P value <0.001; 
a.  Dependent variable was defined as natural log of error in measuring 3MSE (ln(101-3MSE))
b.  Adjusted for baseline age, education, gender, diabetes, history of stroke, and smoking status  
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Figure 3.1 Cross-Sectional Relationship between Nonlinear Pulse Pressure and 




























Figure 3.2 Longitudinal and Cross-Sectional Relationship between Concurrent 



































Subject with initial PP=80 Subject with initial PP=30
*Longitudinal relation: change rate was approxiamtely 1%
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CHAPTER 4 
THE ASSOCIATION BETWEEN ANTIHYPERTENSIVE TREATMENT AND 
INCIDENCE OF DEMENTIA/CIND IN HYPERTENSIVE PATIENTS:  A 
POPULATION-BASED COHORT STUDY OF ELDERLY MEXICAN 
AMERICANS 
4.1 Abstract 
OBJECTIVE:  Longitudinal observational studies examining the relationship between 
antihypertensive treatment and the development of cognitive impairment/dementia in the 
elderly have produced inconsistent results.  Existing studies have been limited in their 
assessment of medications by class.  The objective of this study was to evaluate the 
association between uses of any antihypertensive treatment and specific class of agents 
with incidence of dementia/CIND, over 6 years of follow-up among older Mexican 
American hypertensive patients living in the Sacramento, California area. 
RESEARCH DESIGN AND METHODS: The Sacramento Area Latino Study of Aging 
(SALSA) was a prospective longitudinal cohort study with an average length of 6.11 year 
follow-up.  Among 1789 eligible community-dwelling, non-institutionalized Latinos aged 
60 years and older enrolled in 1998-99, 1434 hypertensive patients who were free 
dementia or “cognitively impaired not demented” (CIND) at baseline were included in 
the analysis.  A multistage process was used to evaluate participants for cognitive 
impairment and dementia at baseline and at six follow-up examinations.  At baseline and 
each follow-up visit, Modified Mini-Mental State Examination (3MSE) and the Spanish 
and English Verbal Learning Test (SEVLT) were used for screening, and the Spanish 
English Neuropsychological Assessment Scales (SENAS battery) and the Informant 
Questionnaire on Cognitive Decline in the Elderly (IQCODE) were used to determine the 
need for a neuro-clinical evaluation.  Clinical assessment and adjudication, as well as 
further magnetic resonance imaging and appropriate laboratory tests were performed to 
establish a dementia case.  In this analysis, dementia and CIND were combined into one 
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outcome variable: dementia/CIND.  Antihypertensive medication use was ascertained at 
each participant’s home at baseline and each follow-up visit by direct inspection of all 
medication and coded by the Centers for Disease Control (CDC) protocol.  Any 
antihypertensive drug use, as well as use of each antihypertensive drug class including 
diuretics, beta blockers, ACE inhibitors, and calcium channel blockers was used as an 
exposure variable in the analysis.   Cox proportional hazard models, using age as time-
scale, were applied to assess the association between use of antihypertensive treatment as 
well as each antihypertensive drug class and the risk of dementia/CIND. 
RESULTS:  Any antihypertensive medication use was associated with lower incidence 
of dementia/CIND after adjustment for potential confounders: hazard ratio (HR=0.42, 
95% CI=0.28, 0.62).  Diuretics, beta blocker, and ACE Inhibitor use were associated with 
lower incidence of dementia/CIND:  (HR=0.52, 95% CI=0.34, 0.81) for diuretics; 
(HR=0.54, 95% CI =0.33, 0.88) for beta blockers; (HR=0.64, 95% CI =0.43, 0.98) for 
ACE Inhibitors.  Calcium channel blockers were not associated with incidence of 
dementia/CIND: (HR=0.93, 95% CI =0.59, 1.47). 
CONCLUSION:  In this large population-based study in which antihypertensive 
medication use was prevalent, any antihypertensive medication use was associated with 
lower incidence of dementia/CIND.  In particular, use of diuretics, beta blockers and 
ACE Inhibitors was associated with a lower incidence of dementia/CIND.  Use of 
calcium channel blockers was not associated with incidence of dementia/CIND.  The 
findings provided additional evidence to support the protective effects of antihypertensive 
treatment and specific drug class on dementia and added to our understanding to potential 
treatment options to preserve cognitive function.  Future epidemiological and clinical 
studies to examine the possible neuro-protective effects of these drugs in diversified 
population are suggested.  
4.2 Introduction 
Several classes of antihypertensive agents are available for treating high blood 
pressure.   Randomized clinical trials have shown that blood pressure-lowering produces 
significant reductions in stroke and cardiovascular risk (1).   It was reported that a 
decrease of 10-mm Hg in systolic blood pressure or 5-mm Hg in diastolic blood pressure 
could lead to a risk reduction of 50% to 60% of stroke death and 40% to 50% of death 
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due to cardiovascular disease or other vascular causes (2).  Stroke and underlying causes 
of cardiovascular disease such as atherosclerosis and arteriolosclerosis have been linked 
to a greater risk of dementia and Alzheimer’s disease (5-13).  However, clinical and 
epidemiological studies investigating the effect of antihypertensive treatment on 
cognitive impairment have provided varied results (14-25), mostly depending on class of 
antihypertensive agents used, study design, length of follow-up, study population, and 
duration of treatment, etc.   
Given the evident beneficial effect of antihypertensive medication in preventing 
stroke and cardiovascular disease, it will be a challenge to conduct placebo-controlled 
clinical trials to examine the relationship of antihypertensive therapy and dementia due to 
ethical complication (18).   Thus epidemiological studies involving longer follow-up and 
multiple visits, larger sample of demented cases, and diversified population will add 
value to a better understanding with the treatment to the modifiable risk factor of 
cognitive dysfunction.  Our objective in this study was to evaluate the association of 
antihypertensive treatment including specific class of agents with incidence of 
dementia/CIND, over 6 years of annual follow-up among older Mexican American 
hypertensive patients living in the Sacramento, California area. 
4.3 Method 
Study population: The Sacramento Area Latino Study of Aging (SALSA) was a 
prospective longitudinal cohort study designed to examine whether risk factors (diabetes, 
hypertension, smoking and obesity) increase the risk of dementia, memory loss, 
functional impairment, and decline in cognitive and physical functioning (26). A detailed 
description of sampling and recruitment in the SALSA study has been described 
elsewhere (26).  The eligible participants were community-dwelling, non-institutionalized 
Latinos aged 60 years and older in 1998-1999, who lived in the Sacramento area and San 
Joaquin Valley in California. At baseline, a total of 1789 people were enrolled in the 
study, and followed from 1998/99 through 2007.  The average length of follow-up was 
6.11 years and the maximum length was 9 years.   Among the 1789 SALSA participants, 
115 had dementia or CIND at baseline and were excluded from this study.   This analysis 
was confined to hypertensive patients whose systolic blood pressure was ≥140 mm Hg 
and/or diastolic blood pressure was ≥90 mm Hg or who took any antihypertensive drugs, 
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at baseline or over 6 years of follow-up.  Thus, the analytical sample included 1434 
participants who met the criteria of hypertensive patient and were free dementia/CIND at 
baseline.   
Data collection: All baseline and follow-up data were collected by interviews and 
clinical assessments at home visits every 12-15 months from 1998/99 through 2007.  To 
maintain contact and gather updated information about health status and medication use, 
a brief telephone interview was added midway between each home visit.   
Outcome measurement –Dementia or CIND:  A multistage process was used to 
evaluate participants for cognitive impairment and dementia at baseline and at the annual 
follow-up examination.  The details of this process are described elsewhere (26).  Briefly, 
in the first stage, a participant who had the screen score below the 20th percentile on 
either 3MSE or SEVLT was referred for further neuropsychological examination.  At 
each follow-up visit, a participant was referred for neuropsychological testing if the 
3MSE score or SEVLT score declined by more than 8 points or 3 points from baseline 
respectively, or if the current 3MSE or SEVLT score was <20th percentile.  In the second 
stage, the SENAS battery and IQCODE were used to determine if a subject was in need 
of a neuro-clinical evaluation with the study geriatrician or a neurologist.  A participant 
was referred for neurological examination if he/she scored below the 10th percentile on at 
least one neuropsychological test and less than 20th percentile on the IQCODE, or scored 
below the 10th percentile on at least 4 neuropsychological tests and less than 40th 
percentile on the IQCODE.  In the third stage, diagnoses of dementia, CIND, or normal 
were adjudicated by a team of neurologists and a neuropsychologist.  Finally, demented 
cases were referred for further magnetic resonance imaging (MRI) and appropriate 
laboratory tests.  Diagnostic and Statistical Manual of Mental Disorder, 4th edition (DSM-
IV) criteria were used to establish a diagnosis of dementia (27).  For this study, dementia 
and CIND were combined into one outcome variable: dementia/CIND (28).   
Exposure measurement - Antihypertensive Treatment:  Antihypertensive 
medication use was ascertained at each participant’s home at baseline and at each annual 
visit by direct inspection of all medication.  The medication information was entered by 
trained personnel onto a collection form, and included the medication code, dose, number 
of prescribed pills, and average number of pills taken.  This information was then updated 
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by telephone every 6-8 months between home visits.  Medication codes were assigned 
using the Centers for Disease Control (CDC) Ambulatory Care Drug Database System 
(29).  Antihypertensive medications included all medication potentially used for lowering 
blood pressure.  In addition, the class of each antihypertensive drug (diuretics, beta 
blockers, ACE inhibitors, and calcium channel blockers) was also used as an exposure 
variable in the analysis.  
Covariate measurement:  The measurements of nine baseline covariates were 
included in the analyses.  They include age, measured in years, calculated from dates of 
birth and baseline visit; sex; education, measured in years, collected at the baseline visit; 
waist circumference, measured at the level of maximum indentation over the abdomen, 
when the participant bended to the side, taken in centimeters at baseline and converted to 
inches; smoking status, assessed by asking each participant to select one of three 
responses that best described their smoking status at the baseline visit:  never smoker, 
former smoker, or current smoker; medical insurance, assessed by asking each participant 
if he/she had medical insurance and types of insurance (e.g. HMP/PPO, MEDI-
CAL/Supplement, Medicare, Others) that he/she had; history of stroke, determined by 
self report of a physician’s diagnosis at the baseline visit;  history of heart disease, 
determined by self report of a physician’s diagnosis at baseline by answering “yes” to the 
questions about MI, angina pectoris, or congestive heart failure;  diabetes, ascertained if a 
participant met the following 3 criteria at baseline:  fasting plasma glucose (FPG) level 
≥126 mg/dL (7.0 mmol/L) (fasting was defined as no caloric intake for at least 8 hours), 
or use of an anti-diabetic medication, or self-report of a doctor’s diagnosis of diabetes.   
Statistical analyses:  Descriptive statistics were used to compare baseline 
characteristics between treated and untreated hypertensive patients.  The crude incidence 
rates were calculated as the number of dementia/CIND patients divided by the follow-up 
time (person-years at risk).  Cox proportional hazard models, using age as time-scale (30-
31), were applied to assess the association between antihypertensive treatment use and 
risk of dementia/CIND.  This time scale considered participants at risk for 
dementia/CIND beginning with their age at entry in the study and allowed adjustment for 
left truncation (30).  Participants who developed dementia/CIND during the follow-up 
contributed information up to their age at diagnosis.  Those who did not develop 
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dementia/CIND during the study were censored at the age of their last available follow-
up visit.  The use of hypertension medication was included in the COX model as a time-
varying exposure variable.  Lagging was used in the analysis to reduce ambiguity in the 
causal ordering (30):  time-varying hypertension medication use was measured at the 
prior visit when dementia/CIND was diagnosed or when the last visit was available.  It 
was counted up to and including Visit 5 (out of 6 follow-up visits) with a lag value of 
hypertension medication use.    
Both unadjusted and adjusted effects of antihypertensive treatment use were 
examined.   Prior knowledge of biological plausibility, the change-in-estimate criterion, 
and differences in baseline characteristics in treated and untreated groups were 
considered when determining covariates to be included in the final models.  The 
covariates used for adjustment in the final models were gender, education (years) 
diabetes (yes/no), history of stroke (yes/no), heart disease (yes/no), smoking status 
(current/former/never smoker), medical insurance, and waist circumference (inches) at 
baseline.   
All models were fit using SAS PROC PHREG for COX models.  Results were 
considered as statistically significant if P<0.05.   
4.4 Results 
Demographic characteristics:  The baseline characteristics of all hypertensive 
patients at baseline are presented in Table 4.1.  The two groups (treated vs. untreated) 
were balanced with respect to gender, education and diastolic blood pressure.  Patients in 
the treated group were older, had higher systolic blood pressure, higher pulse pressure, 
and proportionally more had a history of heart disease, diabetes, stroke, and abdominal 
obesity.  A larger proportion of the patients in the treated group had medical insurance 
and fewer treated patients were current smokers.   
Antihypertensive medications use:  Figure 4.1 shows antihypertensive medication 
use among hypertensive patients over time.  The proportion of hypertensive patients 
using any antihypertensive drugs increased during the 6-years of follow up period from 
49% at baseline to 74% at 6th visit.  The use of the medication by class (diuretics, ACE 
inhibitor, and beta blockers) in this group followed the same upward trend with an 
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increase in use from 21%, 17%, and 11% at baseline to 38%, 32%, and 28% at 6th visit, 
respectively.  The use of calcium channel blockers, however, changed little over time.         
Crude Incidence of Dementia/CIND, Death, and Loss- to-Follow-up:  Among 
1434 hypertensive patients without prevalent dementia/CIND at baseline, 139 patients 
developed dementia/CIND over 6 years of follow-up.  Table 4.2 presents the crude 
incidence rates of dementia/CIND by gender and by hypertension medication use at 
baseline.  The crude rate ratio of users vs. non users was 1.15 for men and 1.2 for women.    
Table 4.3 provides a summary of the number of incident dementia/CIND cases by visit, 
as well as the number of deaths, and number of participants who were lost-to-follow-up.   
Time-Dependent Model:   Table 4.4 presents the unadjusted and adjusted results 
from COX proportional hazard model using time-varying antihypertensive treatment as 
an exposure variable:  in the unadjusted model (model 1), any antihypertensive drug use 
significantly reduced the risk of dementia/CIND by 47% compared with persons not 
using any antihypertensive treatments; after adjusting for baseline stroke and diabetes 
(model 2), the magnitude of this reduction in risk of dementia/CIND among 
antihypertensive treatment users increased further (58%); when further adjusting for all 
potential confounders in the model (model 3), the magnitude of  the reduction in the risk 
of dementia/CIND remained unchanged (58%).    
Table 4.5 presents the association between use of individual antihypertensive 
medication subclasses and incidence of dementia/CIND among hypertensive patients.  
Use of diuretics, the first line therapy for hypertension, led to the largest reduction (48%) 
in incidence of dementia/CIND compared to those who did not use diuretics.  Use of 
beta-blockers and ACE inhibitors, also resulted in a significant reduction (46% and 36%, 
respectively) in the risk of dementia//CIND respectively compared to non-users of these 
classes of drugs.  A non-significant risk reduction for dementia/CIND among users of 
calcium channel blockers was observed.     
4.5 Discussion 
In this community-based prospective cohort study of Mexican Americans aged 60 
and older, the association between use of antihypertensive treatment and the risk of 
developing dementia/CIND among hypertensive patients was examined.  Results 
revealed a significantly reduced risk of dementia/CIND among patients routinely using 
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any antihypertensive medication.  By class, use of diuretics, beta blockers, and ACE 
inhibitors were associated with lower incidence of dementia/CIND.  Use of calcium 
channel blockers, however, was not associated with a reduction in the incidence of 
dementia/CIND.  Statistical significance persists in all adjusted models, regardless of 
whether duration of study or age at diagnosis was used as a time-scale in the analysis.  
Controlling for baseline systolic blood pressure and diastolic blood pressure in all models 
did not change the results.  
Among four epidemiological studies that reported protective effects of 
antihypertensive medications (17-20), the Kungsholmen project showed that diuretic use, 
the most commonly used therapy, was associated with a significant reduction of dementia 
risk (17).  The Cache County Study suggested beneficial effects of diuretic use, in 
particular, potassium-sparing diuretics, and a marginal protective influence from beta 
blockers, on Alzheimer’s disease incidence (20).  The Rotterdam study (18) demonstrated 
a substantial effect of antihypertensive therapy in reducing the risk of dementia and 
vascular dementia. In a longitudinal community-based study of African Americans, 
protective effects of antihypertensive drugs on cognitive impairment were observed (19).  
Our findings in this study are consistent with these results.  On the other hand, the 
Baltimore Longitudinal Study of Aging, which prospectively collected the use of calcium 
channel blockers for up to 19 years, and both the Cache County Study and a community-
based study of African Americans, found no association between use of calcium channel 
blockers and Alzheimer’s disease or cognitive impairment (16, 19-20).   Although all 
three studies indicated a trend toward risk reduction with use of calcium channel 
blockers, results for this class of medication (including ours) were not statistically 
significant.   
Six large randomized placebo-controlled trials that have evaluated the effects of 
antihypertensive treatment on cognitive decline and development of dementia have 
produced divergent results (21-25, 32-33):  The Perindopril Protection Against Recurrent 
Stroke Study (PROGRESS) and the Heart Outcomes Prevention Evaluation (HOPE) 
study reported respectively a 34% reduction of dementia in recurrent stroke patients, and 
a 41% reduction of cognitive decline related to stroke, using ACE inhibitors in both trials, 
or combined ACE inhibitor with diuretics in the PROGRESS (25, 32).  The Systolic 
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Hypertension in the Elderly Program (SHEP) and Medical Research Council's treatment 
trial (MRC) found no significant risk reduction in dementia or cognitive decline in the 
group receiving active treatment of diuretics and/or beta-blockers compared to placebo 
(21, 33).  However, re-analysis of SHEP data indicated that differential drop-out may 
have biased the cognitive assessment and obscured a protective effect of treatment on 
dementia and cognitive decline (34).   In the Systolic Hypertension in Europe trial 
(SYST-EUR), active treatment was a calcium channel blocker (nitrendipine), combined 
with an ACE inhibitor (enalapril) and/or a diuretic (hydrochlorothiazide), if necessary 
(22-23).  This trial demonstrated that active treatment reduced dementia in elderly people 
with isolated systolic hypertension by 50% and 55%, respectively in the initial and 
extended trials (22-23).  The Study on Cognition and Prognosis in the Elderly (SCOPE) 
evaluated the role of ARB candesartan in preventing cognitive decline and subsequent 
dementia among elderly with mild and moderately raised blood pressure (24) and failed 
to observe a significant difference in dementia incidence and cognitive decline between 
the active treated and placebo groups.  This lack of protective effect may be partially 
explained by the fact that most patients in the placebo group were treated with other 
antihypertensive drugs for ethical reasons.  In general, our findings appear consistent with 
results from these trials in that there is protective effect from ACE inhibitors and there 
likely exists potential protective effect from diuretics and beta-blockers.   
The precise mechanisms by which antihypertensive therapy affects dementia 
incidence are not fully understood.  Through blood pressure reduction, antihypertensive 
drugs may lower the risk of progressing into dementia (including both Alzheimer’s 
disease and vascular dementia) by correcting the underlying blood pressure-related 
mechanisms such as hypertension-induced stroke, cerebrovascular damage, and cerebral 
hypofusion, and by disrupting the atherosclerotic process.  For example, the PROGRESS 
study showed that the antihypertensive treatment comprised of an ACE inhibitor 
(perindopril) and a diuretic (indapamide) reduced white matter lesion progression among 
patients with a history of cerebrovascular disease (35), which provides neuron protection 
against cognitive decline and subsequent dementia.  The non-blood pressure related effect 
is mediated by mechanisms other than blood pressure reduction.  For example, calcium 
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channel blockers prevent calcium influx that may cause neuronal death due to release of 
intracellular enzymes (16). 
The important strengths of this analysis include the advantage of a prospective 
longitudinal design with an average of 6-years follow-up, annual home inspection of 
medications in addition to semi-annually phone interviews, annual assessment of 
cognitive function, clinical evaluation and adjudications of potential dementia/CIND 
cases, and further examination of demented cases by magnetic resonance imaging and 
appropriate laboratory tests.  In addition, higher prevalence of antihypertensive 
medication use in this population allowed for the examination of effects of specific 
classes of antihypertensive agents.   Our study is one of the few longitudinal studies 
which examined the use of antihypertensive medications, measured cognitive 
performance, and evaluated dementia incidence at more than 2 follow-up visits.  This 
method of data collection strengthened measurement reliability and may have provided a 
more accurate evaluation of the association between antihypertensive treatment and 
incidence of dementia/CIND.  Limitations in this study include the relatively small 
number of dementia cases, which did not allow for the examination of the association 
between antihypertensive therapy and Alzheimer’s disease and vascular dementia, 
separately, and the potential for differential drop-out due to health problems such as 
severe hypertension or dementia.  Additional limitations may include competing risk 
from death and the potential for residual confounding due to omitted covariates 
associated with exposure and outcome.  This study only included elderly Mexican 
Americans, which may limit the generalizability of the results to other elderly 
populations.       
Identifying appropriate therapeutic strategies to prevent or delay the onset of 
dementia and the progression from cognitive impairment to dementia is of great public 
health importance given that the projected size of the dementia population is expected to 
double every 20 years to 81.1 million worldwide by 2040 (36).  This study provides 
additional evidence to support the protective effects of antihypertensive treatment, 
specifically, diuretics, beta-blockers, and ACE inhibitors, on reducing the risk of 
dementia/CIND.   These findings need to be replicated in future studies with longer 
follow-up and multiple measurements of cognitive function and drug usage, and in larger 
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and more diversified populations; ideally, in the interventional studies specifically 





4.6 Tables and Figures 
 






         Male 285 (41) 323 (44)      0.2
         Female 411 (59) 409 (56)
Age (years) 
         Mean (SD) 71.03 (7.05) 69.61 (6.35) <0.0001
         Median (Minimum, Maximum) 70 (60, 98) 68.61 (59, 92)
Education (Years)
         Mean (SD) 7.43 (5.27)  7.47 (5.35) 0.8956
         Median (Minimum, Maximum) 7.0 (0, 32) 7.0 (0, 24)
Smoking Status [N(%)]
        Never 309 (44) 330 (45) 0.008
        Former Smoker 323 (46) 301 (41)
        Current Smoker 64 (10) 103 (14)
Waist circumference (inches)
Mean (SD) 39.13 (5.25) 37.64 (5.21)  <.0001
        Median (Minimum, Maximum) 39 (18, 58) 38.0 (16, 55)
Medical Insurance [N(%)]
          Yes 658 (95) 647 (88) <0.0001
          No 38 (5) 85 (12)
History of Stroke [N(%)]
         Yes 76 (11) 40 (5) 0.0002
         No 620 (89) 694 (95)
Diabetes [N(%)] (c)
        Yes 325 (47) 160 (22) <0.0001
        No 371 (53) 574 (78)
Heart Disease [N(%)] (d)
Yes 169 (24) 49 (7) <0.0001
        No 527 (76) 587  (93)
Systolic Blood Pressure 
Mean (SD) 142.49 (19.53) 138.05 (18.34)  <.0001
Median (Minimum, Maximum) 140 (90, 230) 138.0 (99, 215)
Diastolic Blood Pressure 
Mean (SD) 76.62 (11.47) 76.50 (9.83) 0.8282
Median (Minimum, Maximum) 77 (40, 113) 76.0 (34, 119)
a.  Hypertensive patient is defined as a patient who had SBP >=140 mm Hg, or DBP >=90 mmHg, or was on any 
hypertension medication during the study period
b.  Any hypertension medication use at baseline.  Two patients had missing hypertension medication use at baseline.
c.  Participants were considered to have diabetes if they met any of the following 3 criteria:  Fasting plasma glucose (FPG) 
level >=126 mg/dL (7.0 mmol/L); or use of an antidiabetic medication; or self report of a physician’s diagnosis of diabetes.
d.  Participants were considered to have heart disease if they had the following 3 medical conditions: MI, angina pectoris, 
or congestive heart failure.   
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Table 4.2 Summary of Crude Incidence of Dementia/CIND by Gender and 
Antihypertensive Medication (AH) Use at Baseline 
 
Male Female
Incidence (per 1000 PY) Incidence (per 1000 PY)
  AH Use = Yes
N=25
14.6 per 1000 PY
N=46
17.8 per 1000 PY
  AH Use = No
N=27
12.7 per 1000 PY
N=41
14.7 per 1000 PY
  Total Rate 
N=52
13.5 per 1000 PY
N=87
16.2 per 1000 PY






Table 4.3 Dementia, Death, Lost to Follow-up by Visit among Hypertensive Patients 
(a) 
 
BL AV1 FV2 FV3 FV4 FV5 FV6
N=1434 N=1429 N=1359 N=1314 N=1205 N=1004 N=883
Dementia/CIND (b) 0 19 (1.3%) 9 (0.7%) 33 (2.5%) 31 (2.6%) 26 (2.6%) 21 (2.4%)
Death 0 25 (1.7%) 27(2.0%) 39 (3.0%) 87 (7.2%) 64 (6.4%) 50 (5.7%)
Lost to follow-up (c) 2 (0.3%) 26 (1.8%) 9 (0.7%) 37 (2.8%) 83 (6.9%) 31 (3.1%) 17 (1.9%)
a. Participant with baseline dementia and CIND were excluded
b. Inclide 22 dementia patients who died
c. Include drop-out and lost to follow-up
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Table 4.4 Association between Antihypertensive Medication Use and Incidence of 
Dementia/CIND among Hypertensive Patients (a) 
Model/Varaible (b) Hazard Ratio  95 % Confidence Interval P Value 
Model 1 (Unadjusted)
   Any Hypertension 
Drugs 0.53 0.370       0.758 0.0005
Model 2 (Adjusted) (c)
   Any Hypertension 
Drugs 0.424  0.292     0.614  <.0001
Model 3 (Adjusted) (d)
   Any Hypertension 
Drugs 0.418  0.284     0.616  <.0001 
a.  Hypertensive patient is defined as a patient who had SBP >=140 mm Hg, or DBP >=90 mmHg, or 
was on any hypertension medication during the study period
b.  Cox proportional hazard models: any hypertensione medications use was a time dependent variable.  
The medication use at the prior vsist (lag value) was used in the models.  Age was used as time scale.     
c.  Adjusted for baseline diabetes and history of stroke
d.  Adjusted for baseline education, gender, diabetes, history of stroke, heart disease, smoking status, 
waist circumference, medical insurance  
 
 
Table 4.5 Association between Antihypertensive Medication Use and Incidence of 
Dementia/CIND among Hypertensive Patients – by Drug Class (a) 
Model/Varaible (b) Hazard Ratio  95 % Confidence Interval P Value 
Model 1 (c)
Diuretics 0.524  0.339     0.808 0.004
Model 2  (c)
ACE Inhibitor 0.644  0.425     0.975 0.038
Model 3  (c)
Beta Blocker 0.538  0.329     0.880 0.014
Model 4  (c)
Calcium Channel Blockers 0.93   0.587     1.472 0.754
a.  Hypertensive patient is defined as a patient who had SBP >=140 mm Hg, or DBP >=90mmHg, or was 
on any hypertension medication during the study period
b.  Cox proportional hazard models: any hypertensione medications use was a time dependent variable.  
The medication use at the prior vsist (lag value) was used in the models.  Age was used as time scale.     
c. Adjusted for baseline education, gender, diabetes, history of stroke, heart disease, smoking status, 
waist circumference, medical insurance 
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SUMMARY AND CONCLUSION 
5.1 Major Findings  
In this community-based prospective cohort study of elderly Mexican Americans, 
the relationships between systolic blood pressure, diastolic blood pressure, and pulse 
pressure and cognitive decline, and antihypertensive treatment and the risk of developing 
dementia/CIND were examined.  The major findings are outlined below.  
The association between systolic blood pressure and cognitive decline:  (i) Higher 
baseline systolic blood pressure was associated with longitudinal decline in cognitive 
performance assessed by 3MSE and SEVLT; (ii) Higher concurrent systolic blood 
pressure was related to longitudinal decline in 3MSE performance among untreated 
participants and the annual decline in 3MSE performance was more pronounced among 
untreated individuals with uncontrolled systolic blood pressure; (iii) Higher concurrent 
systolic blood pressure was associated with lower mean level of cognitive performance 
assessed by 3MSE and SEVLT and treated individuals with uncontrolled systolic blood 
pressure were more vulnerable to the deleterious effect of high systolic blood pressure. 
The association between diastolic blood pressure and cognitive decline:  (i) 
Higher concurrent diastolic blood pressure was associated with longitudinal improvement 
in cognitive performance assessed by 3MSE and SEVLT and this longitudinal 
improvement appeared more pronounced among individuals with low diastolic blood 
pressure; (ii) Higher baseline diastolic blood pressure was associated with longitudinal 
improvement in SEVLT scores.  
The association between pulse pressure and cognitive decline:  (i) Higher baseline 
pulse pressure was associated with longitudinal decline in cognitive performance 
assessed by 3MSE and SEVLT; (ii) Higher concurrent pulse pressure was related to 
longitudinal decline in 3MSE performance; (iii) Higher concurrent pulse pressure was 
related to longitudinal decline in cognitive performance assessed by 3MSE and SEVLT 
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among untreated participants and the annual decline of cognitive performance in both 
tests was more pronounced among untreated individuals with higher pulse pressure (>=70 
mmHg); (iv) There was a U shaped relationship between concurrent pulse pressure and 
mean level of cognitive performance assessed by 3MSE and SEVLT:  both low and high 
pulse pressure was associated with poor cognitive performance.  
The association between antihypertensive treatment and dementia/CIND:  (i) 
There was a statistically significant reduction in the incidence of dementia/CIND among 
any antihypertensive treatment users compared to non-users after adjustment for all 
potential confounders; (ii)  Use of diuretics, beta-blockers, and ACE inhibitors was 
associated with a lower incidence of dementia/CIND after adjusting for potential 
confounders; (iii) Use of calcium channel blockers was not associated with the incidence 
of dementia/CIND after adjusting for potential confounders.   
 5.2 Public Health Implications  
Hypertension, cognitive impairment, and dementia are major threats to the health 
of elderly persons.  Among people aged 65 years and over in the US, more than half have 
isolated systolic or combined systolic-diastolic hypertension (1).  Dementia, on the other 
hand, affects about 5% of the elderly population aged 65 and older in the US, and its 
prevalence doubles every 5 years to exceed 30% in people aged 85 years and older (2-3).  
In addition, the prevalence of cognitive impairment without dementia among individuals 
aged 71 and older was 22.1%, comprising approximately 5.4 million elderly in US in 
2002 (4).   
The mechanisms that link elevated systolic blood pressure, low diastolic blood 
pressure, and high pulse pressure in late life to cognitive decline and dementia are 
biologically plausible.  This study adds to the growing evidence that supports the 
contribution of higher systolic blood pressure, lower diastolic blood pressure, and higher 
pulse pressure to a decline in cognitive function over time in elderly persons.  The 
findings that antihypertensive therapy, specifically, diuretics, beta-blockers, and ACE 
inhibitors, may have protective effects, support on-going efforts to identify appropriate 
therapy to prevent or delay the onset of dementia and the progression from cognitive 
impairment to dementia.  The results of this study point to likely modifiable risk factors 
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for cognitive decline and dementia and add to our understanding of the potential 
usefulness of the treatment options.   
Dementia and cognitive impairment, while adversely affecting patients’ quality of 
life, add a significant burden to patients’ caregivers and to the current health care system.  
Given the high prevalence of hypertension and dementia in the elderly and the 
association between these two conditions, the beneficial effect of early intervention can 
be substantial, even if there is only a small reduction in risk or slight delay to the onset of 
cognitive loss and dementia (6).  Based on current projections for Alzheimer’s disease 
prevalence over the next half century, a 6 month delay in the onset of Alzheimer’s 
disease, would result in almost 400,000 fewer cases by 2047 and a 5-year delay in onset 
would reduce the prevalence by half (5).   
Furthermore, few studies investigating the relationship between blood pressure, 
pulse pressure, or antihypertensive treatment and cognitive dysfunction have included the 
non-White Hispanic population, one of the fastest growing ethnic populations in the US.  
This study provides important information on this rarely studied but rapidly expanding 
population of elderly persons.   
5.3 Limitations 
Several limitations of this study are worth noting.  First, the measurement of 
cognitive decline was restricted to two tests.  It is possible that a broader range of 
cognitive function testing may have captured more occurrences of cognitive decline.  It is 
likely that this outcome misclassification is non-differential (not dependent on exposure), 
which would have the effect of attenuating the relationship between blood pressure/pulse 
pressure and cognitive function over time.   
Second, the relatively small sample of dementia cases did not permit for a 
separate investigation of the association between antihypertensive treatment and 
Alzheimer’s disease and vascular dementia.  Therefore, the conclusions of this study 
apply broadly to all dementia cases in this population. 
Third, as with all observational studies of certain duration, this analysis may be 
vulnerable to the differential drop out of participants due to severe hypertension and 
dementia.  If proportionally fewer treated hypertensive patients drop out of the study due 
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to severe hypertension and dementia than untreated patients, this may lead to an 
underestimate of the protective effect of antihypertensive treatment.  Similarly, if 
proportionally more participants with higher systolic blood pressure drop out of the study 
due to hypertension or cognitive impairment than those with normal blood pressure, this 
may lead to an underestimate of the documented inverse association between higher 
systolic blood pressure and decline in cognitive function.   
 Fourth, there may be a competing risk from death due to the very advanced age 
and medical condition of this population.   When using the COX proportional model, 
competing risk from death was taken into account by examining the association between 
antihypertensive treatment and risk of dementia/CIND by event type (7).  The impact of 
competing risk from death on the relationship between blood pressure and pulse pressure 
and decline in cognitive function, is difficult to quantify due to lack of available exposure 
and outcome information for those who died.  Previous studies indicate that systolic 
blood pressure increases with age for men and women, while diastolic blood pressure 
begins to decline after the age of 60 for both genders (8).  Among the elderly persons 
who died due to age and medical conditions, cognitive function could have declined if 
they were alive.  Thus, a possible impact of competing risk from death may be an 
attenuation of the association between blood pressure and pulse pressure, and decline in 
cognitive function over time.        
Fifth, there may continue to be residual confounding due to unknown or 
unmeasured covariates associated with both exposure and outcome.  The direction of the 
bias due to an unknown or unmeasured confounder depends on the relationship of the 
confounder with exposure and outcome.  The confounder may positively confound the 
estimated association if the confounder-exposure (C-E) association and the confounder-
outcome (C-O) association are in the same direction, which would underestimate the 
protective effect of antihypertensive treatment, or overestimate the inverse association 
between blood pressure and pulse pressure and decline in cognitive function.  The 
confounder may negatively confound the estimated association if the C-E or C-O 
associations are in opposite directions, which would overestimate the protective effect of 
antihypertensive treatment, or underestimate the inverse association between blood 
pressure and pulse pressure and decline in cognitive function (9). 
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 Lastly, this study was confined solely to elderly Mexican Americans, which may 
limit the generalizability of the results to other elderly populations.       
5.4 Directions for Future Research  
These findings that there is a protective effect of antihypertensive treatment on the 
risk reduction in dementia/CIND, and untreated individuals with uncontrolled systolic 
blood pressure or higher pulse pressure have the highest risk of cognitive impairment 
suggest the need to further understand the beneficial effect of antihypertensive treatment, 
in particular, the specific class of agents most capable of preserving cognitive function in 
late life.  Antihypertensive treatment as primary prevention or as treatment of cognitive 
impairment will require further study.  Future clinical trials specifically designed to 
address the association between each drug class (or drug) and the risk of dementia and 
cognitive impairment would be best able to accomplish these goals.   
The findings that higher systolic blood pressure and lower diastolic blood 
pressure in late life are associated with cognitive decline over time raise the need to 
further understand and quantify the optimal blood pressure that preserves cognitive 
function.  While treatment of hypertension and high pulse pressure may prevent arterial 
stiffness and preserve cognitive function, excessive blood pressure reduction in the 
elderly may be deleterious to cerebral perfusion which may in turn affect cognition.  
Thus, future studies investigating the association between antihypertensive treatment and 
cognitive function in elderly should explore how factors such as treatment duration, 
cumulative dosage, age, blood pressure change over time, and cerebrovascular and 
cardiovascular risk influence this association.   
Given the evident beneficial effect of antihypertensive medication in preventing 
stroke and cardiovascular disease, it will be a challenge to conduct placebo-controlled 
clinical trials to examine the relationship of antihypertensive therapy and dementia for 
ethical reasons (10).   Thus, larger and long term epidemiological studies in 
heterogeneous populations will have to be designed to allow for repeated measurements 
of drug use (including dose and duration) and cognitive evaluation.  Such studies will 
increase our understanding of the optimal treatments to address the modifiable risk 
factors for cognitive impairment. 
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5.5 Conclusion  
Results of 6 years of follow-up data from the SALSA study demonstrate that 
higher systolic blood pressure and higher pulse pressure were associated with 
longitudinal decline in cognitive function after adjusting for potential confounding 
variables; and untreated individuals with uncontrolled systolic blood pressure and high 
pulse pressure were at highest risk of cognitive impairment.  There was a U shaped 
relation of concurrent pulse pressure to cognitive function:  both low and high pulse 
pressure were associated with poor cognitive performance.  In addition, the results show 
that higher diastolic blood pressure was associated with longitudinal improvement in 
cognitive function after adjusting for potential confounding variables and this 
longitudinal improvement was more pronounced among individuals with low diastolic 
blood pressure.   
Furthermore, the results of this study indicate that any antihypertensive 
medication use was associated with lower incidence of dementia/CIND.  In particular, 
use of diuretics, beta blockers and ACE Inhibitors was associated with a lower incidence 
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